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ABSTRACT 
 
 Xanthone derivatives are frequently isolated from natural sources, having a wide 
range of pharmacological activities. Thus, these structures have attracted great interest and a 
large variety of synthetic xanthone derivatives have emerged. LEM2 is a synthetic xanthone 
derivative with tested antitumor effect in different cell lines. Xanthone derivatives frequently 
present poor aqueous solubility and nanosystems might present an attractive strategy to 
overcome this limitation.  
 Liposomes represent a versatile system for drug delivery, in the nanometer and 
micrometer scale. Liposomes have already demonstrated to be adequate systems for the use 
in cancer chemotherapy. However, liposomes present physical and chemical instability, 
limiting their shelf-life. In this context, proliposomes, dry phospholipid powders, emerge as 
an alternative to overcome the instability of liposomes. 
 In this dissertation, proliposomal formulations were developed to encapsulate the 
synthetic xanthonic compound LEM2. Three methods were used to produce proliposomes: 
film deposition on carrier, freeze drying and spray drying. After their production, 
proliposomes were hydrated to form liposomes.  
 The three methods produced proliposomes which, on hydration, formed liposomes in 
the nanometer scale, which were efficient in encapsulating LEM2. It was found that 30 days 
after the production of proliposomes by film deposition on carrier and freeze drying, the 
liposomes obtained by their hydration present altered properties, reflecting some instability. 
On the contrary, the spray dried proliposomes presented good stability after 30 days of their 
production, presenting a promising strategy to obtain liposomes with improved stability. 
 
 
Keywords: xanthone; cancer; antitumor; nanotechnology; liposomes; proliposomes.   
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RESUMO 
 
 Derivados xantónicos são frequentemente isolados de fontes naturais, tendo uma 
variedade de atividades farmacológicas. Por isso, estas estruturas têm atraído um grande 
interesse e uma grande variedade de derivados xantónicos sintéticos têm surgido. LEM2 é 
um derivado xantónico de origem sintética com efeito antitumoral testado em diferentes 
linhas celulares. Os derivados xantónicos apresentam frequentemente fraca solubilidade em 
sistemas aquosos e o uso de nanossistemas poderá representar uma estratégica atrativa para 
ultrapassar esta limitação. 
 Os lipossomas representam um sistema versátil para a libertação de fármacos, na 
escala manométrica e micrométrica. Os lipossomas já demonstraram ser adequados para uso 
em quimioterapia no cancro. No entanto, os lipossomas apresentam instabilidade física e 
química, limitando o seu tempo de vida útil. Neste contexto, os prolipossomas, pós de 
fosfolípidos secos, surgem como uma alternativa para ultrapassar a instabilidade dos 
lipossomas.  
 Nesta dissertação, foram desenvolvidas formulações de prolipossomas para 
encapsular o derivado xantónico sintético LEM2. Foram usados três métodos para produzor 
prolipossomas: film deposition on carrier, liofilização e spray drying. Após a sua produção, 
os prolipossomas foram hidratados e a para formar lipossomas.  
 Os três métodos produziram prolipossomas que, quando hidratados, conseguiram 
formar prolipossomas na escala nanométrica, que demonstraram ser eficientes na 
encapsulação do LEM2. Foi descoberto que 30 dias após a produção dos prolipossomas por 
film deposition on carrier and freeze drying, os lipossomas gerados pela sua hidratação 
apresentam propriedades alteradas, refletindo alguma instabilidade. Pelo contrário, os 
prolipossomas produzidos por spray drying apresentaram boa estabilidade ao fim de 30 dias, 
representando uma estratégia promissora para obter lipossomas com melhor estabilidade. 
 
 
Palavras-chave: xantona; cancro; antitumoral; nanotecnologia; lipossomas; prolipossomas.   
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ABBREVIATIONS  
 
ΔH – Enthaplpy variation 
BPO - Benzoyl peroxide  
CEQUIMED – Centro de Química Medicinal da Universidade do Porto 
CH - Cholesterol 
DMPC – Dimyristoyl phosphatidylcholine 
DPPC – Dipalmitoyl phosphatodylcholine 
DSC – Differential scanning calorimetry 
EPC  - Egg phosphatidylcholine 
EPR – Enhanced permeation and retention 
FD – Freeze drying 
FDC – Film deposition on carrier 
HPLC – High Performance Liquid Chromatography 
IUPAC - International Union of Pure and Applied Chemistry 
LUV – Large unilamellar vesicles 
MLV – Multilamellar vesicles 
MW – Microwave  
NBS - N-bromosuccinimide 
PC – Phosphatidylcholine 
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RES – Reticuloendothelial system 
Rf – Retention factor 
SD – Spray drying 
SPC – Soya phosphatidylcholine 
SUV – Small unilamellar vesicles 
TLC – Thin layer chromatography 
Tm – Phase transition temperature 
UV – Ultraviolet light  
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OUTLINE OF THE DISSERTATION 
 
The present dissertation consists of seven chapters. This dissertation involves three main 
areas of research: synthesis of formylated xanthone LEM2, development of an HPLC method 
to quantify LEM2 and development of proliposomal formulations to encapsulate LEM2.  
 
 
CHAPTER 1 – INTRODUCTION 
 
The introductory chapter of the present dissertation is divided in four sections. In the first 
part, a briefly overview about cancer nanotechnology will be presented and in the second will 
be focused on liposomes as drug delivery systems suitable for application in cancer 
nanotechnology, with their advantages and drawbacks being highlighted. In the third part, 
proliposomes will be presented as a promising strategy to overcome the drawbacks presented 
by liposomes. And in the fourth part, a brief introduction to xanthone derivatives will be given 
and their use in nanossystems will be justified. 
 
 
CHAPTER 2 – AIMS 
 
Herein, the main objectives of the present dissertation are described. 
 
 
CHAPTER 3 - RESULTS AND DISCUSSION 
 
Results are subdivided in five sections. In the first part, the different reaction steps for the 
synthesis of carbaldehydic xanthone LEM2 will be described. The second part will present 
the development of a HPLC method for the quantification of LEM2. The third part will show 
the analysis of surface morphology and thermal behavior of proliposomes. The fourth part 
will show the characterization of the liposomes obtained by hydration of proliposomes. The 
fifth part will present stability results of proliposomes. 
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CHAPTER 4 – CONCLUSIONS  
 
This chapter includes the general conclusions of the present dissertation. 
 
 
CHAPTER 5 - MATERIAL AND METHODS 
 
In this chapter, the experimental procedures for the synthesis of LEM2 will be detailed. The 
HPLC conditions for the development of an HPLC method to quantify LEM2 will be detailed. 
The procedures for the proliposome production and their analysis will be described in detail. 
The hydration of proliposomes and the characterization of the obtained liposomes will also be 
described. The conditions used to access the stability of proliposomes will be specified and the 
statistical tests and software will be identified. 
 
 
CHAPTER 6 – REFERENCES  
 
The references will be presented at the end of this dissertation. The references followed the 
American Chemical Society style guide. The main bibliographic research motors were ISI Web 
of Knowledge, from Thomson Reuters, Scopus, and Google. 
 
 
CHAPTER 7 – APPENDICES 
 
This section will include the resume of data for the characterization of liposomes obtained by 
hydration of proliposomes that were used to construct the box and whiskers plots used to 
present the results. 
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CHAPTER 1 – INTRODUCTION 
 
1.1. Cancer nanotechnology 
 
Cancer is one  of the leading causes of mortality worldwide, with approximately 8.2 
million related deaths in 2012 1. Cancer begins as localized disease but spreads to different 
sites within the body, which difficults treatment. The most common treatments are 
chemotherapy, radiation and surgery. Chemotherapy in general presents a number of 
drawbacks, such as nonspecific distribution of antitumor drugs, inadequate drug 
concentrations reaching the tumor site, cytotoxicity, difficult monitoring of therapeutic 
responses and development of multiple drug resistances 2. Considering this, there is an 
emerging necessity to develop alternatives to improve cancer treatment.  
Ideally, the therapeutic agent should reach the tumor sites in the desired 
concentration to destroy the cancerous cells, while minimizing damage to normal cells 2. 
Nanotechnology, which commonly refers structures that are up to several nanometers in size, 
emerges as one of the most promising fields in cancer therapy 3. Cancer nanotechnology is an 
upcoming field concerning interdisciplinary research, involving biology, chemistry, 
engineering and medicine, and its applicability in cancer detection, diagnosis and treatment 
deserves considerable attention 2, 4.  
Nanosystems applied to cancer treatment present unique properties: (i) they can 
themselves have therapeutic properties; (ii) they might carry a large amount of therapeutic 
agent; (iii) their surface can be modified with targeting ligands, increasing the affinity and 
specificity for target cells and tissues; (iv) they can accommodate multiple drug molecules for 
combinatorial cancer therapy and (v) can overcome drug resistance mechanisms 2. 
Nanotechnology can use passive and active targeting strategies to specifically deliver 
drugs into cancer cells, therefore enhancing the anticancer effect, and simultaneously 
minimizing toxicity in normal cells. Passive targeting exploits the characteristics of tumor 
growth (Figure 1A), while active targeting is based on molecular recognition processes 
(Figure 1B) 2-3. 
Passive targeting takes advantage of the size of nanoparticles and the anatomical and 
functional differences between normal and tumor vasculature to confine the drug delivery 
(Figure 1A). Commonly, the vasculature of tumors is highly heterogeneous, having areas of 
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vascular necrosis and densely vascularized areas supplying oxygen and nutrients which 
enhance tumor growth. Angiogenic blood vessels present a high proportion of proliferating 
endothelial cells with aberrant underlying basement membrane compared to normal blood 
cells. In addition, tumor tissues have a leaky and defective architecture, with increased 
fenestrations between adjacent endothelial cells and the microvessels with enhanced 
permeability. The tumor lymphatic system is also abnormal, leading to fluid retention in 
tumors and high interstitial pressure with an outward convective interstitial fluid, which 
results in metastasis. The combination of the leaky microvasculature and the poor lymphatic 
drainage results in the enhanced permeation and retention (EPR) effect. This induces the 
passive targeting of nanocarriers through their accumulation in the tumor at a higher 
concentration than in the plasma and other tissues, enhancing tumor cytotoxicity (Figure 
1A) 2, 4.  
Active targeting involves the functionalization of surface of nanoparticles with ligands 
to deliver the drug to the pathological site or to cross biological barriers based on molecular 
recognition processes (Figure 1B). The receptor for the ligand should be expressed 
exclusively on tumor cells for the recognition to occur in tumor microenvironment. Usually, 
the internalization occurs via receptor-mediated endocytosis 2, 4. 
 
 
Figure 1 - Schematic representation of passive (A) and active (B) targeting of nanoparticles to tumors. Figure 
adapted from 3.  
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1.2. Liposomes 
 
 Liposomes, first reported by Bangham et al. in 1965 5, are microscopic spherical 
vesicles, in which an aqueous environment is entirely enclosed by a concentric bilayer of 
phospholipids 5-8. These vesicular systems are lyotropic liquid crystals with size varying from  
20 nanometers to 20 micrometers 9-10. Liposomes have been extensively studied for their 
application in drug delivery, drug targeting, controlled release and increased solubility of 
drugs 7, 10-11.   
 Liposomes are similar to biological membranes, since they are mainly composed of 
phospholipids, which are amphiphilic molecules with a hydrophilic head and a hydrophobic 
tail (Figure 2) 10.  
 
 
Figure 2 - Representation of the hydrophilic and hydrophobic portions of a phospholipid. 
 
Phospholipids are naturally prone to self-assembly, which leads to their spontaneous 
aggregation in aqueous environments. In the presence of water, phospholipids align 
themselves in a thermodynamically stable manner in planar bilayer sheets, minimizing the 
unfavorable interactions between the bulk aqueous phase and the long fatty acid chains. The 
heads of the phospholipids form a surface facing the water, while the hydrocarbon tails are 
repelled by water and face each other, creating a lipid bilayer (Figure 3A). Therefore, in a 
cell, two layers of heads are formed facing the outside and the inside of the cell, attracted to 
both aqueous environments. The hydrocarbon tails of both layers face each other, thus the 
resultant structure forms a bilayer (Figure 3A). When membrane phospholipids are 
disrupted, they can reassemble themselves into tiny spheres, smaller than a normal cell, 
HYDROPHILIC 
HEAD
HYDROPHOBIC 
TAIL
30 
 
either as monolayers or bilayers. The monolayer structures are called micelles (Figure 3B)  
and the bilayer structures are liposomes (Figure 4A) 8. The organization of amphiphiles in 
the form of bilayer sheets occurs due to the high entropy of the system, caused by the 
interaction forces between the water and the hydrophobic hydrocarbon chains. These 
interactions are eliminated when the sheets fold themselves into sealed vesicles 8, 10, 12. Thus, 
liposomes (Figure 4) form spontaneously when the phospholipids are exposed to an aqueous 
environment, since this is the more energetically stable form 13. 
  
 
Figure 3 - Schematic representation of monolayer structures formed by phospholipids: lipid bilayer (A), micelle 
(B). 
 
Phospholipids confer an amphiphilic nature to liposomes, thus they have a hydrophilic 
inner core surrounded by a hydrophobic membrane. This vesicular organization allows the 
entrapment of both hydrophilic and hydrophobic drugs. Water soluble drugs may be 
solubilized in the internal aqueous compartment of the liposome which difficults and 
therefore slows down its passage through lipid bilayers. A hydrophobic drug can be dissolved 
in the hydrophobic part of the liposome or bind to the membrane. Usually,  lipophilic drugs 
exhibit higher encapsulation efficiencies than hydrophilic drugs 8-9. Lipophilic drugs are more 
likely to remain encapsulated during storage due to their partition coefficients. They associate 
with lipid bilayers, thus avoiding leaking out to the exterior water phase 9. 
 Liposomes can be classified according to the number of bilayers entrapping the 
internal aqueous volume into unilamellar or multilamellar vesicles. If liposomes have just one 
bilayer they are classified as unilamellar vesicles (Figure 4A), and their properties are 
similar to those of flat surfaces. Depending on their size, unilamellar vesicles can be separated 
into small unilamellar vesicles (SUV) with a diameter ranging from 20 to 100 nm, or large 
unilamellar vesicles (LUV), with a diameter from 100 nm to 1 µm. SUV exhibit large 
curvature, while LUV presents a low curvature. If there is more than one bilayer, liposomes 
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are considered to be multilamellar vesicles (MLV) (Figure 4B). MLV represent a 
heterogeneous group with respect to size and morphology of the liposomes. Usually, MLVs 
present a size range from 100 nm to 20µm. Each concentric layer of liposomes has a thickness 
of about 4 nm 9-10, 14. Typically, unilamellar vesicles are suitable for entrapment of hydrophilic 
drugs in the internal-aqueous space, while MLVs are appropriate to entrap lipophilic drugs 10.  
 
 
Figure 4 - Schematic representation of two different types of liposomes: unilamellar vesicle (A) and multilamellar 
vesicle (B). ( ) represents a water molecule. 
  
 Liposomes, as drug delivery systems, need to show appropriate chemical and 
biological stability. Colloidal stable structures on equilibrium, such as liposomes, are less 
sensitive to external changes than equilibrium structures, such as micelles. Thereby, 
liposomes are suitable for pharmaceutical applications. Biological stability is related to the 
retention of the drug in its target and to the control of the clearance rate of liposomes from 
the blood system and from certain parts of the body. The clearance rate depends on the dose, 
size and surface charge of liposomes.  
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1.2.1. Composition of liposomes 
  
Glycerophospholipids are commonly used phospholipids in liposomal formulations. 
Glycerophospholipids are composed of a glycerol molecule (C3H8O3) covalently attached to 
two fatty acid chains (with variable levels of saturation) by ester linkages and to a highly polar 
or charged group by a phosphodiester linkage in the third carbon. Glycerol acts as a backbone, 
by its attachment to the fatty acid chains and to the phosphate group. The hydrophobic tail of 
phospholipids is composed by the two fatty acid chains and the hydrophilic head is made of 
glycerol, phosphate and a polar group 10, 15. Glycerophospholipids are derivatives of 
phosphatidic acid (Figure 5), in which phosphate group bears a negative charge at neutral 
pH 15.  
 
   
Figure 5 - Phosphatidic acid structure. 
 
The polar head group of glycerophospholipids might be neutral, negatively charged or 
positively charged 15. The charge of phospholipids determine the overall surface charge of 
liposomes 9. The most common phospholipid is phosphatidylcholine (PC), which has choline 
as polar head group and presents a neutral net charge (Figure 6) 10, 15-16.  
 
  
Figure 6 – Phosphatidylcholine structure. 
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Phospholipids might be natural or synthec. Phosphatidylcholine from natural sources 
includes soya phosphatidylcholine (SPC) and egg phosphatidylcholine (EPC). Dimyristoyl 
phosphatidylcholine (DMPC) and dipalmitoyl phosphatidylcholine (DPPC) are examples of 
synthetic phosphatidylcholine (Figure 7) 10. 
 
 
Figure 7 - Dimyristoyl phosphatidylcholine and dipalmitoyl phosphatidylcholine structures. 
 
The structure and flexibility of lipid bilayers are influenced by the temperature. Below 
physiological temperatures, the bilayer lipids are in a semisolid gel phase. In this state, the 
polar head groups are uniformly displayed at the surface and the acyl chains are packed, and 
with no motion. Above physiological temperatures, the hydrocarbon chains are in constant 
motion, producing a fluid state, also known as liquid-disordered state, in which the interior of 
the bilayer is more fluid than solid. At physiological temperatures, lipids are in the liquid-
ordered state, where the acyl chains of lipids suffer less thermal motion, but there is a lateral 
movement in the bilayer plane. The phase transition temperature (Tm) is the temperature at 
which occurs the transition between the semisolid gel phase and the liquid-disordered state, 
where the phospholipid bilayer becomes more leaky and flexible. Each type pf phospholipid 
has a specific Tm. The hydration of phospholipids above the Tm, allows them to assemble into 
liposomes 10, 17.  
Cholesterol, a steroid molecule (Figure 8), might be incorporated in liposome 
bilayers to modify the membrane fluidity, reduce the permeability of water soluble molecules 
through the membrane, and improve its stability 10. It functions as a fluidity buffer. Below Tm, 
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cholesterol makes the membrane more disordered and  permeable, while above Tm, it causes 
membrane organization, stabilizing it 14. Since the formation of liposomes is achieved by 
hydration of phospholipids above their Tm, cholesterol enhances the rigidity of liposomes, 
possibly by filling the gaps between the phospholipid molecules in the bilayer structures 10, 18. 
Besides, the presence of cholesterol in the bilayer membranes improves its stability in the 
presence of biological fluids, such as blood/plasma. In the absence of cholesterol, liposomes 
tend to react with blood proteins, being destabilized. Cholesterol appears to reduce this 
interaction. However, the presence of cholesterol does not entirely prevent the loss of 
liposomal phospholipids 19.  
Cholesterol molecules arrange themselves among the phospholipid molecules with the 
hydroxy group facing towards the water phase and the tricyclic ring trapped between the first 
few carbons of the fatty acyl chains, into the hydrocarbon core of the bilayer 19.  
 
 
Figure 8 – Chemical structure of the molecule cholesterol. 
 
1.2.2. Liposomes in cancer nanotechnology 
 
In clinical applications, liposomes have proven to take advantage of the EPR effect to 
passively accumulate in regions of enhanced vasculature permeability, when their average 
diameter is <200 nm. Thus, the drug-mediated delivery by liposomes explores the 
overexpression of fenestrations in the cancer vasculature to increase drug concentration in 
tumor sites. This results in reduced side effects and toxicity of the encapsulated drugs as 
opposed to free drugs, as well as an increased therapeutic index 4, 11. 
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Table I- Marketed liposomal products for cancer treatment. 
Product Drug Indications Reference(s) 
Doxil/Caelyx 
(Johnson & 
Johnson) 
 
Myocet (Cephalon) 
 
 
 
Doxorubicin 
Kaposi’s 
sarcoma; 
ovarian 
cancer; breast 
cancer; 
multiple 
myeloma 
20-23 
DaunoXome 
(Galen) 
 
 
 
Daunorubicin 
Kaposi’s 
sarcoma 
24 
Marqibo (Talon) 
 
 
 
Vincristine 
Acute 
lymphoblastic 
leukemia 
25-26 
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Liposomes might also prolong the residence time of drugs in circulation for an 
effective drug delivery. Cells of the reticuloendothelial system (RES) act as immunological 
barriers to effective targeting of nanoparticles. The surface of liposomes might be modified 
with the polymer polyetlylene glycol to avoid the uptake by the RES and increase the 
circulatory half-time. Therefore, the targeting of liposomes within the tumor is enhanced 4, 9. 
Several liposomal products encapsulating drugs have been introduced in the market and 
many other drugs are in clinical trials. Table I shows the approved liposomal products for 
cancer treatment in the market. The parenteral route of administration is predominant for 
the clinically approved products, in particular intravenous administration 11.  
 
1.2.3. Advantages and drawbacks of liposomes 
 
 Liposomes have attracted considerable interest as drug delivery systems since they are 
versatile drug carriers, suitable for the encapsulation of both hydrophilic and hydrophobic 
substances. Also, these vesicular structures allow the encapsulation of both small molecules, 
with the size of an ion, and large molecules of several hundred thousand Daltons 9, 27. 
Liposomes present a number of advantages over conventional dosage forms (Table II). They 
have shown to be relatively non‐toxic, biodegradable, biocompatible, weakly immunogenic 
(produce no antigenic or pyrogenic reactions). These properties, like size, charge and surface 
can be readily handled by the addition of new ingredients to the lipid mixture before the 
preparation of liposomes or by using different preparation methods. Liposome vesicles act as 
drug reservoirs, thus protecting drugs from the external environment, such as enzymes and 
inhibitors. These agents could lead to its inactivation of drugs encapsulated in liposomes. 
Encapsulation of drugs can increase their stability, avoiding rapid degradation 8-9. Also, 
liposome formulations have the ability to control the drug release rate in the presence of 
biological fluids, retaining a relatively constant and, effective drug concentration in the 
circulation. Therefore, they can prevent undesirable side effects and reduce drug toxicity 9, 28.  
The possibility of targeting liposomes to a particular type of cell or organ leads to the 
increase of its efficacy and therapeutic index, mainly due to the alteration of biodistribution.  
Manipulating liposomes for a selective uptake is another way of reducing drug toxicity and 
injurious side effects because of the minimized drug distribution of the drug. Besides, 
liposomal drug delivery systems enable the delivery of higher drug concentrations to the 
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desired target. Moreover, drug encapsulation results in enhanced pharmacokinetic properties, 
such as reduced elimination or prolonged residence time of the drug in systemic circulation 8-
9.  
Despite all the advantages of using liposomes as drug delivery systems, this strategy 
presents a few drawbacks mainly related to their large scale manufacture (Table II). There is 
a necessity to obtain large quantities of the product with reproducible properties and to 
demonstrate suitable stability during storage and before administration.  However, liposomes 
exhibit poor chemical and physical stability, which restricts its storage for a long period 10, 27, 
29-30.    
 
Table II - Advantages and drawbacks of liposomes as drug delivery systems. 
Advantages Drawbacks 
- Allows the encapsulation of hydrophilic and 
hydrophobic drugs, with a wide range of sizes; 
- Non-toxic, biodegradable, biocompatible, 
weakly immunogenic; 
- Easy handle of their properties; 
- Increased drug stability; 
- Control of the drug’s release rate; 
- Possibility of directing to a specific target; 
- Reduced drug toxicity and adverse side effects; 
- Delivery of superior drug concentrations to the 
desired target. 
- Poor chemical stability; 
- Poor physical stability; 
- Lipid exchange between liposomes and 
HDLs in plasma; 
- Reduced shelf-life. 
 
 
  Physical instability of aqueous dispersion of liposomes occurs due to vesicle 
aggregation and fusion, which leads to an alteration in vesicle size and loss of retained 
material. Problems associated with physical stability of liposomes are important to consider 
when analyzing the appearance, size and size distribution of liposomes 10, 31.  
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Figure 9 - Representation of molecular moietis of phospholipids associated with the chemical instability of 
liposomes. 
 
The chemical instability of these systems is caused by the formation of ice crystals in 
the liposome, which conduces to the destabilization of bilayers resulting in drug leakage. 
Chemical instability is associated with tendency of phospholipids in liposomal formulations to 
suffer hydrolysis and oxidation (Figure 9). Hydrolysis may occur in ester bonds linking the 
glycerol backbone to the fatty acids, leading to the disconnection of the hydrophobic chains. 
In the case of phosphatidylcholine, the hydrolysis might cause the formation of 
lysophosphatidylcholine (Figure 10), increasing the permeability of liposomes.  
 
 
Figure 10 - Structure of lysophosphatidylcholine; R = Fatty acid acyl chain. 
 
Therefore, it is important to keep the levels of lyso-phospholipids to a minimum 
during preparation and storage of liposomes. Oxidation might occur in the presence of 
unsaturated acyl chains, which could change the permeability of liposomes and their shelf life. 
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Oxidation of phospholipids might be minimized by protecting them from light or by the 
addition of antioxidants to the liposomes 10, 19, 31. Oxidation and hydrolysis of lipids may lead 
to the formation of short-chain lipids and then less hydrophobic derivatives appear in the 
bilayers, resulting in compromised quality of liposomes. Besides, the described stability 
problems cause quicker liposome breakdown and altered drug release profile 32.   
In addition, in plasma, liposomes are destabilized due to the lipid exchange between 
liposome and HDLs, leading to aggregation and leakage of the entrapped material 31.  
 The refered drawbacks of liposomal formulations (Figure 11) limit their clinical 
application. Indeed, there is a necessity of developing strategies to improve the characteristics 
of liposomes and, consequently, expanding their applications. 
 
 
Figure 11 - Possible causes of instability of liposomes. 
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1.2. Proliposomes 
 
 Although liposomes have been widely used for drug delivery, the drawbacks cited 
above limit their application for medicinal purposes. To be commercialized, these systems 
need to be stable in the storage time and conditions, and persist intact and active until they 
reach the biological target. The factors affecting the stability of liposomes will affect their shelf 
life and their performance in vivo 27.  
In an attempt to overcome the instability inherent to liposomes, Payne et al. 
introduced, in 1986, a dry phospholipid formulation as an alternative to conventional aqueous 
liposomes, named proliposome 29-30. This approach is based on the ability of membrane lipids 
to form vesicles when they contact with water, enabling the conversion of the proliposome 
preparation into a liposomal dispersion by addition of an aqueous phase 27, 33.  
 Originally, proliposomes were defined by Payne et al. as dry, free-flowing granular 
products composed of drug and lipids which form an isotonic multilamellar liposomal 
suspension, when dispersed in water 30. However, the concept of proliposomes was expanded, 
later in 1991, to include liquid phospholipid formulations that can generate liposomes upon 
addition of aqueous phase 34. These liquid formulations are concentrated ethanolic solutions 
of phospholipids. Thus, proliposomes can be generally defined as powdered or liquid lipid 
formulations that can form liposomes upon addition of aqueous phase and shaking. Usually, 
powdered formulations are better suited to entrap lypophilic drugs because the greater part of 
drug locates into the liposomal lipid phase.  Liquid lipid formulations are suitable for the 
entrapment both hydrophobic and hydrophilic drugs 10. The application of proliposomes is 
extended to several administration routes 35-39. 
 In this work, attention will be given only to powdered lipid proliposomal formulations. 
Powdered proliposomes are composed of a carrier which is a water soluble porous powder, 
usually the polyol sugars mannitol or sorbitol (Figure 12), where phospholipids and the drug 
dissolved in organic solvent might be loaded 28.  
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Figure 12 - Mannitol (A) and sorbitol (B) structures. 
 
Sterilized proliposomes can be stored in a dry state and then dissolved in aqueous 
solution to form a liposomal suspension when necessary 28. The conversion of proliposomes 
into liposomes may take place in vivo by the effect of physiological fluids, or in vitro before 
the administration, by addition of a convenient hydrating fluid above the Tm of the lipid, 
followed by shaking 10, 27.  
Drying an organic solution of phospholipids and a carrier/drug results in the 
formation of particles involving a crystalline carrier/drug at the core encapsulated by a 
phospholipid shell 40. When an aqueous phase is added to proliposomes, the process of 
dissolution/disintegration might occur by a progressive hydration of the lipid surface of 
proliposome. Then, liposomes “bud off” from the central core of the proliposome until 
hydration of the lipid and carrier dissolution is complete 29.  
The fact that proliposomes are accessible in a dry powder form makes them easy to 
distribute, transfer, measure and store and consequently, a useful and economic delivery 
system 10, 27. Besides, proliposomes demonstrated controlled drug release, improved stability 
and increased solubility relatively to conventional liposomes 31. Preparing liposomes by 
conversion from proliposomes allows the encapsulation of a wide variety of drugs with 
different solubility in water and organic solvents and presents high encapsulation efficiencies 
when compared to other methods based on passive entrapment 33.  
Several studies of drug incorporation in proliposomes revealed that these systems 
have the ability to convert a drug from its crystalline form to its amorphous state 35, 41-42. It is 
established that drugs in amorphous state have higher solubility. In this state, 
thermodynamically unstable, since no energy is required to break up the crystal lattice while 
the dissolution process occurs, the drug release is enhanced when in that physical state 43-44.  
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1.3.1. Manufacturing processes  
 
From the variety of manufacturing processes of powdered proliposomes, attention will be 
given to film deposition on carrier, freeze drying and spray drying. 
 
1.3.1.1. Film deposition on carrier 
 
This is the original method used by Payne et.al to produce proliposomes, which 
requires a modified rotary evaporator (Figure 13) 30. It involves a film of drugs and 
phospholipids, which is deposited onto a porous, water soluble carrier material 10.   
The selection of the carrier material is of great importance for formulation of 
powdered proliposomes by film deposition on carrier. It should be selected based on its 
solubility, porosity and ability to accommodate phospholipids on its surface. The particle size 
of the carrier influences the size and polydispersity of the generated liposomes 18. 
The process involves two main steps. First, the selected carrier is placed in a round-
bottom flask, attached to a rotary evaporator and dried under reduced pressure 45-46. In the 
second step, a solution of drug and phospholipids in a volatile organic solvent is sprayed 
dropwise, from a separating funnel to a bed of carrier material, via feed tube (Figure 13) 47-48. 
Thus, a thin film of phospholipid is coated onto the carrier surface and the organic solvent is 
evaporated to obtain a dry granular material 10, 27. The goal of modifying the rotary 
evaporation unit is to ensure the efficient mixing of the formulation components and to 
monitor the temperature of the powder bed 30.  
Preparation of proliposomes using film deposition on carrier method is one of the 
most cost-effective strategies to produce liposomes in large scale. Liposomes formed by this 
method have shown to be similar to conventional liposomes 31. However, the step of the 
addition of the organic solution to the rotary evaporator and its evaporation makes this 
method slow and difficult to control 27.   
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Figure 13 - Apparatus used to prepare proliposomes by film deposition on carrier (from 49). The reproduction of 
this figure was authorized. 
 
1.3.1.2. Freeze drying 
 
Freeze drying, also called lyophilization, implicates heat and mass transfer to and 
from the product that is being prepared. To use this technique, a solution of drug, lipids and a 
carrier material is placed in a freeze dryer, where the procedure occurs. This comprises three 
stages: the freezing stage, consisting in cooling the solution until it is frozen; a primary drying 
stage, in which the frozen solvent is removed by sublimation by action of the vacuum; and a 
second drying stage to remove the solvent that did not freeze 44, 50-51.  
For the success of sublimation step, it is fundamental the avoidance of ice fusion. This 
may be achieved as long as one operates below the triple point of the pressure-temperature 
equilibrium of water, which occurs near the temperature 0 oC and at the absolute pressure of 
4,59 mm Hg (Figure 14). At the triple point, water coexists simultaneously in solid, liquid 
and gaseous states. Below the triple point, it only coexists in the solid and the gaseous states 
(Figure 14), allowing the direct evaporation of the frozen particles, bypassing the liquid state 
of the water 44, 50-51. 
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Freeze drying allows the preservation of chemical properties of substances that might 
be affected by heat for a long period, since the procedure occurs at low temperatures. Also, 
using freeze drying, the drug is subjected to a minimal thermal stress during the solid 
particles formation, minimizing the risk of phase separation as soon as the solution is 
vitrified. Besides, lyophilized products have a sponge structure, allowing their rapid 
dissolution 44, 50. However, freeze drying is time-consuming and expensive 10.  
 
 
Figure 14 - Pressure-temperature equilibrium diagram. At the triple point, solid, liquid and vapor are in dynamic 
equilibrium. Liquid-vapor phase limit ends at the critical point. The normal freeze point is the temperature at 
which the liquid freezes at a pressure of 1 atm and the normal boiling point represents the temperature at which 
the liquid vapor pressure is 1 atm. Adapted from 52. 
  
Freeze drying has already been employed for the drying of liquid liposomal 
formulations with a cryoprotectant, usually a carbohydrate molecule, in order to increase 
their stability. Minimizing the levels of residual water can improve the shelf-life of lyophilized 
liposomes and prevent the increase of vesicle size upon rehydration 53-54. Besides, when the 
method of the film deposition on carrier is employed to produce proliposomal powders, some 
residual organic solvents may still remain in the formulation and freeze drying might be used 
to complete the drying of the powder product 47, 55-56. Also, Fei et al., reported the use of freeze 
drying to directly produce proliposomes 57. 
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1.3.1.3. Spray Drying 
 
 Spray drying has a great utility in pharmaceutical industry, mainly in the production 
of solid dispersions 43, 58, and recently, has also been explored to produce proliposomes for the 
pulmonary delivery of drugs 38, 59-61. Spray drying is characterized by its ability to comprise in 
one step the formation of particle and its drying, which allows a better control of the particle 
formation 18.  
Spray drying converts liquid feed of the drug, which can be a solution, emulsion or 
suspension, into a dry powder 18. Spray drying involves the addition of the carrier material, 
commonly a sugar, to an organic solution comprising the drug and lipids, and its subsequent 
spraying into a stream of heated air flow to remove the solvent 10, 58-59, 62. This process involves 
four stages (Figure 15):  
1) Atomization of the product into a spray nozzle; 
2) Spray-air contact;  
3) Drying of the spray droplets;  
4) Collection of the solid product.  
 
 
Figure 15 – Schematic representation of the stages in the spray drying technique (from 63). The 
reproduction of this figure was authorized. 
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 The solutions subjected to spray drying are pumped and atomized into the drying 
chamber with a spray nozzle, and dried in a concurrent heated air flow that is later collected 
in a reservoir 43, 63. The large surface area of the droplets and the high temperature of the 
drying air leads to the rapid solvent evaporation and formation of the solid dispersion in 
seconds, which might be fast enough to prevent phase separation and to allow thermolabile 
molecules to be converted into fine powder 10, 58.  
 Spray drying parameters exert a great influence in the powder characteristics, such as 
particle size, size distribution, shape, morphology and density, which might be optimized 
since spray drying has the ability to manipulate and control a variety of parameters, including 
the solvent composition, solute concentration, feed rates of solution and gas, temperature and 
droplet size 10, 18.  
Spray drying usually produces drugs in the amorphous state, but occasionally the drug 
may be partially crystallized during processing 62.  
Spray drying allows the production of a fine, dust free powder as well as agglomerated 
to particular specifications, within a narrow range of particles sizes, which makes it especially 
advantageous when it is necessary to prepare particles of uniform size and shape. Also it is 
cost effective, which makes it easy to scale up and suitable for both laboratory and industrial 
scale production of proliposomes 27, 43, 64.  
 Spray drying has also been used for the drying of liposomal formulations. Spray-dried 
liposomes of the drugs verapamil and metronidazole with mannitol as the carrier preserved 
the size distribution of liposomes and entrapment efficiency of the drug after a year of storage 
65. 
 
1.3.2. Proliposomes and anticancer drugs 
 
It is known that the intravenous route is the preferred route for the administration of 
liposomes as drug delivery systems. The studies of proliposomal formulation to encapsulate 
anticancer drugs have also been applied to this route of administration. The anticancer drugs 
studied for encapsulation in proliposomal formulations are presented in Table III. The 
studied proliposomes exhibited good stability for at least 12 months 66. The encapsulation of 
anticancer drugs in liposomes after hydration of proliposomes seems to alter the 
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pharmacokinetic and tissue distribution profiles and increase the therapeutic efficiency when 
compared to an intravenous administration of the free drug 37, 67. 
 
Table III - Anticancer drugs encapsulated in proliposomes. 
Drug Indications Reference(s) 
 
 
Adriamycin 
Solid tumors; 
malignant lymphomas; 
acute leukemia 
68-69 
 
 
Carboplatin 
Ovarian cancer; small 
or non-small cell lung 
cancer; head and neck 
cancer; lung cancer 
67 
 
 
Docetaxel 
Non-small cell lung 
cancer 
37, 66 
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1.3. Xanthones 
 
 Chemically, xanthones are a class of oxygenated heterocyclic compounds with a 
dibenzo--pyrone scaffold (Figure 16) 70-72.  
 
 
Figure 16 - Xanthone scaffold (numbered according IUPAC). 
 
Although xanthone (9H-xanthen-9-one) does not occur in nature, xanthone 
derivatives are frequently isolated as secondary metabolites from plants and microorganisms 
71, 73. These oxygenated heterocycles are structurally related to other natural compounds with 
the γ-pyrone scaffold: flavonoids (Figure 17A) and chromones (Figure 17B) 71. 
 
 
Figure 17 - Scaffolds containing a γ-pyrone moiety: flavonoids (A) and chromones (B). 
 
 Xanthones derivatives from natural sources have attracted great interest due to 
associated large variety of pharmacological activities 71. However, naturally-occurring 
xanthones present a relatively restricted structural diversity since the biosynthetic pathways 
limit the type and position of the substituents in the xanthone scaffold. Naturally occurring 
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xanthone derivatives are subdivided into six major groups: simple oxygenated xanthones, 
glycosylated xanthones, prenylated xanthones and their derivatives, xanthone dimers, 
xanthonolignoids and miscellaneous, depending on the nature of the substituents in the 
dibenzo-γ-pyrone scaffold 74. The use of chemical synthesis expanded the possibilities of 
having substituents from different nature and in different positions on the xanthone scaffold. 
By chemical synthesis, simple functional groups such as hydroxyl, methoxyl, methyl and 
carboxyl have been introduced in the xanthone nucleus, as well as more complex substituents 
such as epoxide, azole, aminoalcohol, sulfamoyl and dihydropyridine, and others 74. 
Xanthones can be considered as “privileged structures”, considering that their scaffold 
contains a rigid ring system allowing the insertion of a variety of substituents capable of 
interacting with several biological targets 75.  
 Among the diversity of biological activities described for natural and synthetic 
xanthones, the in vitro growth inhibitory activity on tumor cell lines seems to be quite 
important, since they exert their effect on a wide range of different tumor cell lines 74, 76-77. 
 Although xanthone derivatives present a broad spectrum of biological activities, most 
of the substituents introduced (by nature or by synthesis) confer poor aqueous solubility, 
which is often linked with poor bioavailability 78. Considering this, micro and nanoparticulate 
systems present an interesting strategy to overcome this solubility problem. In CEQUIMED-
UP, both natural and synthetic xanthone derivatives have been encapsulated in micro and 
nanoparticles containing biocompatible and biodegradable polymers 79-86.  Xanthone 
derivatives incorporated in polymeric microparticles and nanoparticles, and their respective 
biological activities are presented (Table IV). 
 
Table IV - Xanthone derivatives encapsulated in micro and nanoparticles. 
Xanthone derivative Biological 
activity 
Type of 
particles Reference(s) 
 
Xanthone (synthetic) 
Monoamine 
oxidase inhibitor; 
protein kinase C 
activator; inhibitory 
effect on NO 
production  83-84, 87 
Polymeric 
nanoparticles 81, 83-84 
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3-Methoxyxanthone (synthetic) 
Monoamine oxidase 
inhibitor; protein 
kinase C activator; 
inhibitory effect on NO 
production  83-84, 87 
Polymeric 
nanoparticles 81, 83-84 
 
1,3-Dihydroxy-2-
methylxanthone (synthesic) 
Inhibitory effect on the 
growth of a human 
breast cancer cell line 
79 
Polymeric 
nanoparticles 79 
 
3,4-Dihydro-12-hydroxy-2,2-
dimethyl-2H,6H-pyrano[3,2-
b]xanthen-6-one (synthesis) 
Antiproliferative  effect 
on a human breast 
cancer and leukemia 
cell lines; apoptotic 
effect 
in leukemia cell lines 
88-89 
Polymeric 
nanoparticles 80 
 
α-Mangostin (natural) 
Antioxidant; 
neuroprotective; 
antimicrobial; 
antiprotozoal; 
vasorelaxant 90 
Polymeric 
microspheres 91 
 
Mangiferin (natural) 
Antioxidant; anti-
allergic; anthelminthic; 
gastro-protective; 
antitumor; antiviral 82 
Polymeric 
microparticles 
82 
Table IV (cont.) 
51 
 
  In the present work, a carbaldehyde xanthone derivative, LEM2 (Figure 18), which 
was tested for antitumor effect and displayed activity in breast cancer (MCF-7), melanoma 
(UACC-62) and glioma (SF268) cell lines (unpublished results), was synthesized in house in 
suitable amount to be incorporated into proliposomal formulations.  
 
  
Figure 18 - LEM2 structure. 
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CHAPTER 2 – AIMS 
 
LEM2 is a synthetic xanthone with a very promising inhibitory effect on the growth of 
breast cancer, melanoma and glioma cell lines. 
 
 
 
 
Cancer is among one of the leading causes of death worldwide and the treatment 
present a number of associated problems, that nanotechnology has been recently trying to 
overcome. Cancer nanotechnology has emerged as a promising strategy for the therapy of 
cancer diseases. Nanosystems might be rational designed to achieve the desired concentration 
of the drug in tumor sites and minimize the distribution to the normal cells.  
Among the nanosystems, liposomes have adequate properties for drug delivery in 
cancer treatment and several liposomal products with anticancer drugs have been approved 
and are already in the market. 
Although liposomes present good properties as drug delivery systems, they have poor 
chemical and physical stabilities, which could limit their shelf life and performance in vivo. 
The proliposome strategy arises as a mean to overcome the instability inherent to liposomes.  
 
Based on these considerations, the main objectives of the present dissertation are: 
 Synthesize the carbaldehyde xanthone derivative LEM2 with a very promising 
inhibitory effect on the growth of breast cancer, melanoma and glioma cell 
lines in adequate amount to incorporate into proliposomal formulations; 
 Develop an HPLC method for the quantification of LEM2 in proliposomal 
formulations; 
LEM2 
56 
 
 Develop and optimize proliposomal formulations by different methodologies, 
using: 
o Egg phosphatidylcholine 
o Cholesterol 
o Mannitol 
o LEM2 
 Evaluate size, morphology and physical state of proliposomal powders 
obtained from the different methodologies; 
 Evaluate size, zeta potential, entrapment efficiency and morphology of 
liposomes obtained by hydration of solid proliposomes; 
 Evaluate the stability of proliposomes. 
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CHAPTER 3 – RESULTS AND DISCUSSION 
 
3.1. Synthesis of the carbaldehydic xanthone derivative LEM2 
 
LEM2 is a synthetic carbaldehydic xanthone derivative, with poor solubility in water, 
which was tested for its antitumor effect and displayed activity in breast cancer (MCF-7), 
melanoma (UACC-62) and glioma (SF268) cell lines (unpublished results).  
The synthesis of LEM2 was performed according to previous studies and is depicted 
in Scheme 1 92. 
 
 
Scheme 1 - General synthesis of LEM2. r.t. = room temperature; MW = microwave; NBS = N-bromosuccinimide; 
BPO = benzoyl peroxide; [(BMIm)BF4] = 1-butyl-3-methylimidazolium tetrafluoroborate. 
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3.1.1. Synthesis of benzophenone intermediate 3, (2-hydroxy-3,4-
dimethoxy-6-methylphenyl) (methoxyphenyl) methanone  
 
The synthesis of some kind of xanthones can be achieved using benzophenone 
intermediates as precursors. Benzophenone intermediates suitable for cyclisation to 
xanthones may be synthesized by Friedel-Crafts acylation of methoxybenzene derivatives with 
an appropriate substituted benzoyl chloride in the presence of a Lewis acid, as aluminium 
chloride, in ether, at room temperature (Scheme 2) 93.  
 
 
Scheme 2 - Friedel-Crafts acylation of 3,4,5-trimethoxytoluene (1) with 2-methoxybenzoyl chloride (2) to obtain 
the benzophenone intermediate 3. r.t. = room temperature. 
 
To obtain benzophenone intermediate 3, aluminium chloride was added to a dry 
diethyl ether solution of 2-methoxybenzoyl chloride (2) and 3,4,5-trimethoxytoluene (1). The 
reaction occurred under N2, resulting in a deep red mixture. After completing the reaction, 
the suspension was acidified with HCl (5M) to convert the phenolate group of the 
benzophenone derivative (3) to a non-ionized form. Then, the non-ionized form of the 
benzophenone derivative was extracted with chloroform. After drying with anhydrous sodium 
sulphate and concentrate of the organic layer, brown oil was obtained which contains the final 
product. The identity of intermediate 3 was confirmed by TLC comparing with standard 
compound previously obtained 92. The obtained oil (327,8 mg) was used without further 
purification processes for the next reaction step.  
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3.1.2. Synthesis of 3,4-diethyl-1-methyl-9H-xanthen-9-one (4): cyclization 
of benzophenone intermediate 3 
 
The benzophenone intermediate 3 in the crude product from the first reaction was the 
precursor for cyclisation to the xanthone intermediate (Scheme 3). 
 
 
Scheme 3 - Cyclization of the benzophenone intermediate 3 to xanthone intermediate 4. MW = microwave. 
 
The cyclization of benzophenone intermediates under conventional heating is time-
consuming. Hence, it was preferred the use of microwave heating instead of conventional 
heating to obtain the xanthone intermediate 4,  in order to reduce the reaction time 94.  The 
reaction of cyclization was undergone in basic medium, which contributes to the increase of 
the acidity of the phenolic hydroxyl group, leading to a nucleophilic attack to the carbon 
directly bounded to OCH3 and subsequent elimination of methanol. The reaction product 
contained a white solid, insoluble in basic solution, containing the xanthone intermediate 4. 
After completing the reaction, the solid was trapped by a vacuum filtration and after that 
extracted with dichloromethane. The intermediate 4 was present in the organic layer from the 
extraction. The solutions containing the xanthone intermediate 4 were dried, and 3,093 g 
were obtained. The identity of intermediate 4 was confirmed by TLC comparing with the 
standard compound previously obtained 92.  
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3.1.3. Synthesis of 1-(dibromomethyl)-3,4-dimethoxy-9H-xanthen-9-one 
(5) 
 
The dibromated xanthone intermediate 5 can be synthetized via Wohl-Ziegler 
reaction, by a benzylic bromination of xanthone intermediate 4 (Scheme 4). Benzoyl peroxide 
(BPO) acts as a catalyst since its oxygen-oxygen bond is weak, allowing BPO to easily undergo 
homolytic cleavage, providing reactive free radicals to initiate the reaction of benzylic 
bromination. N-bromosuccinimide (NBS) is a source of bromine radicals, largely used for the 
Wohl-Ziegler reaction 95. 
 
 
Scheme 4 - Wohl-Ziegler reaction of dibrominated xanthone intermediate 5 from xanthone intermediate 4. NBS 
= N-bromosuccinimide; BPO = benzoyl peroxide. a isolated yield. 
 
The reaction was performed using carbon tetrachloride as solvent. After completing 
the reaction, some insoluble impurities were trapped by vacuum filtration. The TLC analysis 
revealed that the dibrominated xanthone intermediate 5 was exclusively present in the 
mother liquor and that some impurities were still present. Therefore, the mother liquor was 
submitted to a flash column chromatography and the fractions containing the intermediate 5 
where collected. However, those fractions were found to contain some impurities. 
Consequently, a chromatography flash cartridge was used as an additional purification step. 
The identity of intermediate 5 was confirmed by TLC comparing with the standard compound 
previously obtained 92. The dibrominated xanthone intermediade 5 was obtained with a yield 
of 80%. 
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3.1.4. Synthesis of 3,4-dimethoxy-9-oxo-9H-xanthene-1-carbaldehyde 
(LEM2) 
 
After the synthesis of dibrominated xanthone intermediate 5, it was needed to 
perform the debromination reaction in order to accomplish the oxidation to the carbaldehydic 
xanthone LEM2. For that, an ionic liquid was used, which is a promising strategy for 
debromination. The ionic liquids are classified as green solvents and have been widely 
explored in organic chemistry for the last few years 96. For α-dibromoketones, the use of the 
ionic liquid 1-methyl-3-pentylimidazolium tetrafluoroborate [(pmIm)BF4] under MW 
irradiation can produce either monobromoketones or doubly debrominated ketones 97.  
However, in the present study, the intermediate 5 is a ɣ-dibromoketone and the reaction 
occurred under conventional heating (100 ºC) using the ionic liquid 1-butyl-3-
methylimidazolium tetrafluoroborate [(BMIm)BF4] to afford LEM2 directly by a solvolytic 
displacement of dibrominated xanthone intermediate 5 using water and ionic liquid as 
solvents (Scheme 5).  
 
 
Scheme 5 - Synthesis of carbaldehydic xanthone derivative LEM2 from xanthone intermediate 5. [(BMIm)BF4] 
= 1-butyl-3-methylimidazolium tetrafluoroborate. a isolated yield. 
 
In the course of the reaction, an intense spot with a different Rf of the xanthone 
intermediate 5 was appearing in TLC plates, while the spot corresponding to intermediate 5 
progressively disappeared. After finishing the reaction, the crude material was submitted to a 
liquid-liquid extraction with ethyl acetate in order to remove the ionic liquid and the water 
used in this reaction. The organic layer was dried and submitted to a chromatography flash 
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cartridge to remove the impurities contained on the crude material. The resulting pure 
fractions were collected and concentrated. However, some impure fractions were obtained, 
which were concentrated and crystalized from ethyl acetate/n-hexane. LEM2 purity and 
identity was confirmed by TLC based on comparison with the reference sample previously 
obtained in house 92. The synthesis of xanthone LEM2 was successfully completed with an 
isolated yield of 64%. 
 
 
3.2. Development of an HPLC method for the quantification of LEM2 
  
 To quantify LEM2 in proliposomal formulations, a methodology using High 
Performance Liquid Chromatography (HPLC) equipped with an UV detector was used. The 
UV spectrum of LEM2 was performed, with the wavelength ranging from 200 to 400 nm 
(Figure 19). The maximum absorption of LEM2 occurs at the wavelength 242 nm, which 
was the wavelength chosen to detect the compound by the HPLC method. 
 
 
Figure 19 - UV absorption spectrum of LEM2. 
 
Calibration curves were prepared and analyzed in triplicate on three different days in a 
isocratic elution with the mobile phase water : methanol (25:75) at a flux of 1.0 ml/min. The 
Table V shows the concentration of LEM2 standard solutions and respective medium peak 
areas obtained from the chromatogram of LEM2. Data were fitted to least squares linear 
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regression and a calibration curve was obtained (Figure 20), with the respective equation of 
the curve (Equation 1) having a correlation coefficient (R) of 0.9994. The essay 
demonstrated good linearity in the tested range for LEM2 (R2 = 0.9989) 98.  
 
   
𝑦 = 0.4281𝑥 − 0.0327 
 
Table V - Concentration of LEM2 standard solutions and respective peak areas.  
Concentration (µg/ml) Peak area 
0.25 0.0914 
0.50 0.211 
1.00 0.378 
2.00 0.793 
3.00 1.223 
4.00 1.717 
5.00 2.072 
6.00 2.566 
 
 
 
Figure 20 –Calibration curve to extrapolate LEM2 concentration values using HPLC method. 
Equation 1 
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Figure 21 shows that the standard deviation of the concentration values of LEM2 
standard solutions are randomly dispersed, reinforcing the linearity of the method. 
Figure 22 shows that for the response / concentration relation, most of the points are 
within the value of mean ± 5%. Although, two of the points exceed this value, they fit within 
the ± 10% limit, supporting the linearity of the method.  
 
 
Figure 21 – Graphic of the standard deviation of concentration values of LEM2 standard solutions.  
 
 
Figure 22 - Graphic of response / concentration vs concentration logarithm. 
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 Figure 23 shows a typical chromatogram of LEM2 standard solutions with the 
retention time about 7.3 min for LEM2. 
 
 
Figure 23 – LEM2 standard solution chromatogram.  
 
Figure 24 proves the specificity of the analytical method for LEM2, since the UV 
spectrum obtained from the chromatogram throughout the presented peak, is superposed to 
the LEM2 UV spectrum (Figure 19). 
 
 
Figure 24 – LEM2 standard solution chromatogram and UV spectrum at 242 nm for the specific detection of the 
compound. 
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3.3. Preliminary studies for the development of proliposomal 
formulations 
 
 Proliposome formulations are comprised of a lipid part and a carrier material. For this 
study, the lipid part was composed by a mixture of egg phospholipids with 80% of 
phosphatidylcholine (PC) and cholesterol (CH), and the carrier material used was mannitol. 
Phospholipids from natural sources have lower costs than synthetic phospholipids. Egg and 
soybean are the principal sources of natural phospholipids for production of liposomes, and 
their phase transition occurs at negative temperatures. EPC liposomes present lower leakage 
rates and higher saturation levels than SPC liposomes, which improves their oxidative 
stability 99. These factors are important to consider when producing proliposomes, since the 
main purpose proliposomes is to enhance the stability of liposomes. Cholesterol has the 
ability to enhance the rigidity of liposomes and improve the stability of lipid bilayers in the 
presence of biological fluids, as stated above 10, 18-19. Mannitol is a water soluble sugar, and a 
frequently used carrier material for proliposomal formulations, allowing the production of 
dried powders with loose appearance 46. 
A preliminary study was performed to choose the molar ratio between egg 
phosphatidylcholine and cholesterol to continue the proliposomal formulation studies. 
 Using the method film deposition on carrier, the molar ratio between PC and CH was 
varied, keeping constant the weight ratio between carrier material (mannitol) and the lipid 
(5:1). The molar ratio PC : CH (3:1) was chosen, proliposomes were hydrated with water and 
their characterization is presented in Table VI. 
 
Table VI - Characterization of liposomes formed from the proliposomal formulation PC : CH (3:1) produced by 
film deposition on carrier. 
Effective diameter 
(nm) 
Polydispersity 
Zeta potential 
(mV) 
621.4 ± 31.0 0.341 ± 0.025 -58.46 ± 7.42 
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 Previous studies stated that the amount of carrier material in proliposomal 
formulations is a determinant factor on the properties of powder particles 38, 59-60. Thus, the 
weight ratio between the carrier material and the lipid part was studied, by freeze drying, 
keeping the molar ratio PC : CH (3:1). The liposomes reconstituted from hydration of 
proliposomes are characterized in Figure 25 and 26 (and Appendix I).  
 
 
Figure 25 – Box and whiskers plot of effective diameter of liposomes formed by hydration of proliposomes 
produced by freeze drying, with different carrier : lipid weight ratio. Each box represents three individual batches. 
Statistical significance: * p < 0.009, # 0.003.   
 
The effective diameter of liposomes seems to insignificantly increase when the lipid : 
carrier weight increases from (1 : 1) to (5 : 1) (Figure 25). However, for the ratio (10 : 1), the 
effective diameter significantly decreases comparing to the ratios (2.5 : 1) and (5:1). This could 
be explained by the fact that the presence of the carrier material prevents in some extent the 
interaction between the lipids. So, increasing the amount of carrier material in the 
formulation, lipids have a lower capacity to contact between them, preventing the formation 
of aggregates, thus reducing the particle size of liposomes upon hydration of proliposomes.  
For the studied ratios, the polydispersity indexes were similar, varying from 0,318 ± 0,030 to 
0.328 ± 0.014. The amount of mannitol in the formulation also seems to influence the surface 
charge of liposomes (Figure 26). Similarly to recent findings, the zeta potential becomes 
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insignificantly slight more negative as the weight ratio carrier: lipid increases 100. A previous 
study also demonstrated that zeta potential of vesicular structures decrease when the amount 
of the sugars ribose and maltose increased 101. It seems that the values of zeta potential tend to 
be lower when the amount of sugar in the formulation increases. 
 
 
Figure 26 – Box and whiskers plot of zeta potential of liposomes formed by hydration of proliposomes produced 
by freeze drying, with different carrier : lipid weight ratio. Each box represents three individual batches.  
 
The weight ratio between the carrier material and the lipid part 10:1 seems to form 
dry, free flowing powders. This was not observed for the other studied weight ratios, which 
produced agglomerated and not completely dried powders.  
 The following studies were performed with the molar ratio PC : CH (3:1) and the 
weight ratio carrier : lipid (10:1). 
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3.4. Proliposomal formulation 
 
 Maintaining the referred ratios, different percentages of LEM2 were added to the 
proliposomal formulation, using film deposition on carrier and freeze drying methods. One of 
the studied LEM2 percentages in the proliposomal formulations was also used to produce 
proliposome powders using spray drying method.  
The surface morphology and thermal behavior of the obtained proliposome powders 
were analyzed. 
   
3.4.1. Morphology of proliposome powders 
 
 The surface morphology of the carrier material, mannitol, and of the proliposome 
powders, without the drug and with LEM2, produced by the different methods was examined 
by Scanning Electron Microscopy (SEM).  
For film deposition on carrier, the surface morphology of mannitol with particle size 
<125 µm was observed, before the preparation of proliposomes, and exhibited a porous 
surface (Figure 27A and B). The porous surface is illegible in proliposome powders, without 
the drug (Figure 27C and D) or with LEM2 (Figure 27E and F), because of the 
deposition of phospholipids on the surface of mannitol, as described in earlier studies 35, 102. 
The incorporation of LEM2 in the proliposomal formulation (Figure 27E and F) does not 
seem to introduce major alterations to the surface morphology when compared to the 
proliposome powders with no drug (Figure 27C and D).  
For the freeze drying, a solution of mannitol submitted to freeze drying in the same 
conditions as the solution prepared to produce proliposomes, was observed by SEM. Mannitol 
seems to have some orientation, similar to a crystalline structure (Figure 28A and B). 
Regarding to proliposomal powders, they seem to have heterogeneous shapes, ranging from 
elongated and sharped particles to approximately spherical and porous particles (Figure 
28C and D). The presence of LEM2 does not seem to influence the morphology at surface of 
freeze drying proliposome powders (Figure 28E and F). 
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Figure 27 –SEM images of the surface of mannitol (A-B) and proliposome powders without drug (C-D) and with 
LEM2 (E-F) produce from the film deposition on carrier method. 
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Figure 28  - SEM images of the surface of mannitol (A-B) and proliposome powders without drug (C-D) and with 
LEM2 (E-F) produce from the freeze drying method. 
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Figure 29 - SEM images of the surface of mannitol (A-B) and proliposome powders without drug (C-D) and with 
LEM2 (E-F) produce from the spray drying method. 
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Figure 29 shows the morphology of spray dried mannitol particles and proliposome 
powders produced by spray drying. This method produces spherical particles, with a high 
surface area. In contrast with the film deposition on carrier proliposome powders, the spray 
dried mannitol exhibited a smooth surface (Figure 29A and B) while the proliposomal 
powders presented a porous surface (Figure 29C-D). Rojanarat et al. have demonstrated 
that mannitol has a great importance in the production of spherical particles using spray 
drying 38, 59-60. If the amount of mannitol present in the formulation is not sufficient, irregular 
shaped particles might be obtained. As observed by the other methods, the presence of LEM2 
in spray dried proliposomes does not alter the morphology of the surface of spray drying 
proliposome powders (Figure 29E and F). 
From the three methods, spray drying seems to produce more uniform proliposome 
powdered particles with a porous structure, which might allow a fast dispersion of the powder 
when hydrated to form liposomes 57. Also, for the three methods, the incorporation of LEM2 
within proliposomes did not alter the morphology of the particles, which was already expected 
since the percentage of the compound in the formulation is low (2%).  
 
3.4.2. Thermal behaviour of proliposome powders 
 
 The thermal behavior of proliposome powders was analyzed by differential scanning 
calorimetry (DSC), which evaluates the enthalpy variation (ΔH) and measures how the 
temperature changes the heat capacity of the material 103. 
Figure 30 and Table VII present the DSC data from the components of 
proliposomal formulations. The mannitol peak in thermogram was used a as a reference peak 
for the thermal study of the proliposomal formulations, as it was done in previous studies 38, 
59-60.   
 The DSC thermogram and DSC data from film deposition on carrier proliposomes are 
shown in Figure 31 and Tale VIII. It was observed that proliposomal formulations present a 
temperature onset of approximately 2-6 ºC lower than the observed for the pure mannitol. 
This indicates a possible interaction of mannitol with the lipid part of the formulation, since 
PC and CH both present lower onset temperatures.  
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 The presence of LEM2 in film deposition on carrier proliposomes seems to lead to 
lower enthalpy values and broader peak intervals (Figure 31 and Tale VIII). These 
alterations might be a possible indication of the interaction between LEM2 and mannitol.  
 
 
Figure 30 - DSC thermogram of egg phosphatidylcholine (A), cholesterol (B), mannitol (C) and LEM2 (D). 
 
 
Table VII – DSC data of thermograms of egg phosphatidylcholine, cholesterol, mannitol and LEM2. 
Formulation Area 
(J/g) 
Onset 
(ºC) 
Peak  
(ºC) 
End 
(ºC) 
PC -12.0 7.3 19.3 25.9 
CH -7.0 42.1 45.6 50.5 
Mannitol  -30o.8 166.2 170.5 176.7 
LEM2 -135.9 220.1 222.8 224.7 
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Figure 31 – DSC thermograms from -20 ºC to 240 ºC at 10 ºC/min of proliposomes with no drug (A), 0.8% 
LEM2 (B), 2% LEM2 (C) and 4% LEM2 (D) obtained with film deposition on carrier method. 
 
 
Table VIII –DSC data of thermograms of LEM2, mannitol and proliposomes with no drug, and with 0.8%, 2% 
and 4% of LEM2,  obtained with film deposition on carrier method. 
Formulation Area 
(J/g) 
Onset 
(ºC) 
Peak  
(ºC) 
End 
(ºC) 
No drug -304.8 163.8 170.2 173.3 
0.8 % LEM2 -274.5 164.7 174.9 179.8 
2 % LEM2 -260.3 160.4 170.4 174.1 
4 % LEM2 -257.2 161.0 169.7 174.1 
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Figure 32 - DSC thermograms from -20 ºC to 240 ºC at 10 ºC/min of proliposomes with no drug (A), 0,8% 
LEM2 (B), 2% LEM2 (C) and 4% LEM2 (D) obtained with freeze drying method. 
 
 
Table IX – DSC data of LEM2, mannitol and proliposomes with no drug, and with 0,8%, 2% and 4% of LEM2, 
obtained with freeze drying method. 
Formulation Area 
(J/g) 
Onset 
(ºC) 
Peak 
(ºC) 
End 
(ºC) 
No drug -302.5 165.7 169.2 171.2 
0.8% LEM2 -262.2 165.3 168.5 170.2 
2% LEM2 -268.3 165.5 168.9 170.6 
4% LEM2 -263.1 165.5 168.6 170.2 
 
 
Figure 32 and Table IX present DSC thermograms and DSC data of freeze dried 
proliposomes. From the thermograms it was observed the presence of two peaks, indicating 
that the used formulations were below the eutectic composition of the system 104.  
 The presence of lipids in the freeze dried proliposomes did not introduced significant 
alterations to the enthalpy or peak’s temperature. As the observed for film deposition on 
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carrier proliposomes, when LEM2 was introduced in the formulation, the enthalpy 
decreases, possibly due to an interaction of LEM2 with mannitol, the carrier material. 
 For spray dried proliposomes the carrier material used was spray dried mannitol. In 
this case, the reference peak is that on the thermogram of the spray dried mannitol (Figure 
33).  
  
 
Figure 33 - DSC thermogram of spray dried mannitol from -20 ºC to 240 ºC at 10 ºC/min.  
 
Figure 34 and Table X present the DSC thermograms and DSC data of spray dried 
proliposomes. The presence of lipids in the formulation decreases the enthalpy and the onset 
temperature of the peak, revealing the interaction between the lipid part and the carrier 
material of the formulation. The presence of LEM2 in the formulation does not alter the 
onset or the end temperature of the peak. However,LEM2 increases the enthalpy of the peak 
for spray dried proliposomes, as the opposite to film deposition on carrier proliposomes and 
freeze dried proliposomes. This might suggest that using spray dried mannitol, instead of 
commercial mannitol, might alter the type of interaction between LEM2 and mannitol. 
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Figure 34 - DSC thermograms from -20 ºC to 240 ºC at 10 ºC/min of proliposomes with no drug (A), 2% LEM2 
(B) obtained with spray drying method. 
 
Table X –DSC data of LEM2, spray dried mannitol and proliposomes with no drug and with 2% LEM2 obtained 
with spray drying method. 
Sample / 
Formulation 
Area 
(J/g) 
Onset 
(ºC) 
Peak 
(ºC) 
End 
(ºC) 
Spray dried 
mannitol 
-277.1 163.5 169.9 172.5 
No drug -201.3 159.6 167.2 170.1 
2% LEM2 -240.4 159.6 167.2 170.2 
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3.5. Hydration of proliposomes 
 
Membrane lipids tend to form vesicles when in contact with water 27, 33. Thus, the proliposome 
powders were hydrated using miliQ water and agitated to obtain liposomal dispersions, and 
then filtered through a 5 µm filter. Liposomes were characterized regarding to surface 
morphology, size of particles, surface charge and entrapment efficiency of LEM2.    
 
3.5.1. Morphology of liposome dispersions  
 
 Figure 35 shows the surface morphology of the particles obtained by hydration of 
proliposomes produced by film deposition on carrier. It was observed the formation of 
particles having a spherical shape, which are attributed to liposomal vesicles. However, 
particles with a not completely spherical structure could also be observed (Figure 35A and 
C). Besides, the hydration of proliposomes can also lead to formation of an uncommon type 
of structure (Figure 35B and D), which seems to be a vacuole-like structure, with a 
diameter of 4-5 µm and comprising in its interior a number of irregular particles at the 
nanometer scale. The diameter of liposomes, either without drug or with LEM2, ranges from 
hundreds of nanometers to a few micrometers (Figure 35A and C). 
The morphology of the particles formed by hydration of freeze dried proliposomes is 
represented in Figure 36. It was observed that the hydration leads to the formation of 
particles with a more uniform shape than the observed for the film deposition on carrier 
method. Spherical particles from hundreds of nanometers to a few micrometers were 
observed by cryoSEM images (Figure 36). The vacuole-like structures were also observed for 
liposomes generated from freeze dried proliposomes (Figure 36D). However, they seem to 
be present in a lower extent than in the film deposition on carrier method and with smaller 
sizes (around 2 µm).  
The hydration of the spray dried proliposomes originated spherical particles (Figure 
37), with a uniform shape in the nanometer scale. The vacuole-like structures were present in 
cryoSEM images (Figure 37B) at a low extent with a diameter of about 2 µm.  
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Figure 35 - CryoSEM images of liposomes formed by hydration of proliposomes produced by the film deposition 
on carrier method, without drug (A-B) and with 2% of LEM2 (C-D) at x 25000 magnification.  
 
 
Figure 36 - CryoSEM images of liposomes formed by hydration of proliposomes produced by the freeze drying 
method,  without drug (A-B) and with 2% of LEM2 (C-D) at x 25000 magnification. 
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Figure 37 - CryoSEM images of liposomes formed by hydration of proliposomes produced by the spray drying 
method,  without drug (A-B) and with 2% of LEM2 (C-D) at x 25000 magnification. 
 
Liposomes obtained by hydration of spray dried proliposomes presented a smaller size 
than liposomes formed by hydration of proliposomes produced by both film deposition on 
carrier and freeze drying methods.   
The vacuole-like structures were observed for the three analyzed methods, with a 
higher extent for the film deposition on carrier method. For the freeze drying and spray 
drying methods, these structures were less evident and presented smaller diameters. 
 
3.5.2. Particle size  
 
The effective diameters presented in this work were evaluated by Dynamic Light Scattering 
(DLS), using an apparatus which is suitable to measure the diameter of particles until 5 µm. 
Thus, particles with a higher diameter were not counted for the medium values of effective 
diameter. However, after the hydration of proliposomal formulations, the dispersion was 
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filtered through a 5 µm filter. Considering this, the range of measured diameters seems to be 
appropriated to measure the obtained liposomes. 
Figure 38 presents the intervals and the medium effective diameter of liposomes 
formed by hydration of film deposition on carrier proliposomes. The medium diameter seems 
to insignificantly increase with the presence of LEM2 comparing to the formulation with no 
drug (546.5 ± 66.0 nm). The effective diameter of liposomes with LEM2 ranged from 592.3 ± 
42.6 nm to 659.1 ± 152.37 nm, and it was observed that  increasing the LEM2 percentage in 
the formulation, higher effective diameter values were obtained. However, this difference is 
not statistically significant. 
The effective diameter of liposomes generated by hydration of freeze dried 
proliposomes is shown in Figure 39. The formulation with no drug has a medium effective 
diameter of 443.60 ± 26.80 nm and for the formulations with drug, the medium effective 
diameter values range from 410.83 ± 17.24 nm to 450.63 ± 37.95 nm. Surprisingly, the 
effective diameter insignificantly decreased when the LEM2 percentage was increased. 
   
 
Figure 38 – Box and whiskers plot of effective diameter of liposomes formed by hydration of proliposomes 
produced by film deposition on carrier, with no drug and with different percentages of LEM2. Each box represents 
three individual batches.  
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Figure 39 – Box and whiskers plot of effective diameter of liposomes formed by hydration of proliposomes 
produced by freeze drying, with no drug and with different percentages of LEM2. Each box represents three 
individual batches.  
 
 
Figure 40 – Box and whiskers plot of effective diameter of liposomes formed by hydration of proliposomes 
produced by spray drying, with no drug and with different percentages of LEM2. Each box represents three 
individual batches. 
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The effective diameter of liposomes formed from hydration of spray dried 
proliposomes is present in Figure 40. The formulation with no drug has a medium effective 
diameter of 243,2 ± 34,0 nm and the formulation with 2% of LEM2 has a higher effective 
diameter, of 272,2 ± 20,9 nm. This difference has no statistical significance. 
 From the three studied methods, the effective diameter increases in the following 
order spray drying < freeze drying < film deposition on carrier. 
 The polydispersity indexes of the presented formulations ranged between 0,272 ± 
0,024 and 0,353 ± 0,019 (Appendix II), with the spray drying method presenting the lower 
values. This indicates that all the formulations were polydispersed, which agrees with the 
cryoSEM analysis presented above. The cryoSEM images revealed the presence of particles 
with a wide range of sizes.  
 
3.5.3. Zeta potential  
 
 Zeta potential is a physical property that allows the indirect measurement of the 
surface charge. The magnitude of this property gives an idea about long-term stability of the 
colloidal dispersion. If zeta potential of liposomes in dispersion has a high absolute value, 
there is a tendency for repulsion between the nanoparticles, avoiding flocculation or 
coagulation. Thus, zeta potential value must be more positive than + 30mV or more negative 
than – 30mV, in order to be considered stable by electrostatic repulsion 105. 
 For all the studied formulations, zeta potential was more negative than -30 mV, 
indicating electrostatic stability (Figure 41-43). 
 For all the studied methods, the zeta potential became less negative when LEM2 was 
introduced in the formulation. For the formulations with no drug, zeta potential was between 
-41.84 ± 2.66 mV and -47.38 ± 8.19 mV, while for the formulations with LEM2 the zeta 
potential values ranged from -37.83 ± 1.49 and -38.63 ± 0.40 mV. These differences did not 
present significant statistical meaning. Besides, between the different LEM2 percentages, the 
zeta potential values were similar (Figure 41-42). 
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Figure 41 – Box and whiskers plot of zeta potential of liposomes formed by hydration of proliposomes produced 
by film deposition on carrier, with no drug and with different percentages of LEM2. Each box represents three 
individual batches. 
 
 
Figure 42 – Box and whiskers plot of zeta potential of liposomes formed by hydration of proliposomes produced 
by freeze drying, with no drug and with different percentages of LEM2. Each box represents three individual 
batches. 
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Figure 43 – Box and whiskers plot of zeta potential of liposomes formed by hydration of proliposomes produced 
by spray drying, with no drug and with different percentages of LEM2. Each box represents three individual 
batches. 
 
3.5.4. Entrapment efficiency  
 
 The entrapment efficiency of LEM2 in liposomes obtained by hydration of 
proliposomes was determined by a direct measurement of the compound that was 
encapsulated in the formulation. The quantification of LEM2 was performed by an HPLC 
method. 
 For the film deposition on carrier and freeze drying methods, three percentages of 
LEM2 were studied: 0.8%, 2% and 4%. Figures 44 and 45 demonstrate that the higher 
entrapment efficiency was reached for 2% of LEM2 in the formulation and that at 4% of 
LEM2, the entrapment efficiency was even lower than at 0.8% of LEM2. Apparently, 
liposomes have a limited capacity to entrap LEM2, which is maximal at 2% of LEM2 for the 
total weight of the formulation.  
For the freeze drying method, the entrapment efficiency at 2% of LEM2 (62.68 ± 
31.55 %) was significantly higher than at 4% of LEM2 (4.72 ± 0.55%) (p < 0.05). However, 
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other differences observed in the entrapment efficiency between formulations were not 
statistically relevant. 
Since the entrapment efficiency of liposomes for LEM2 was higher at 2% of the 
compound on the total weight of the proliposomal formulation, this was the chosen 
percentage to produce spray dried proliposomes (Figure 46). 
From the three studied methods, at 2% of LEM2, the entrapment efficiency increases 
in the following order: spray drying (47.54 ± 24.73%) < film deposition on carrier (51.92 ± 
21.91%) < < freeze drying (62.68 ± 31.55%). 
 
 
Figure 44 – Box and whiskers plot of entrapment efficiency of liposomes formed by hydration of proliposomes 
produced by film deposition on carrier, with different percentages of LEM2. Each box represents three individual 
batches. 
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Figure 45 – Box and whiskers plot of entrapment efficiency of liposomes formed by hydration of proliposomes 
produced by freeze drying, with different percentages of LEM2. Each box represents three individual batches. 
Statistical significance: 
*
 p = 0.02. 
   
 
 
Figure 46 – Box and whiskers plot of entrapment efficiency of liposomes formed by hydration of proliposomes 
produced by spray drying, with 2% of LEM2. Each box represents three individual batches.  
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3.6. Stability of proliposomes 
 
 After producing proliposomes, they were kept in a desiccator at room temperature. 
The stability studies were performed up to 30 days. Proliposomes were analyzed by DSC and 
hydrated to characterize the obtained liposomes. 
 
3.6.1. Thermal behavior of proliposome powders 
 
 The DSC thermograms of proliposomes, 30 days after their production exhibited 
overlapping peaks, whit slight alterations comparing to the day of production. 
For film deposition on carrier proliposomes (Figure 47 and Table XI), it seems that 30 days 
after their production, the peak suffer a small shift to higher temperatures and the enthalpy 
was increased. 
For freeze dried proliposomes, the major alteration observed after 30 days of the 
production is the decrease in the enthalpy of the peak (Figure 48 and Table XII). 
 
 
Figure 47 - DSC thermograms from -20 ºC to 240 ºC at 10 ºC/min of proliposomes with 2% of LEM2 at the day 
of production (A) and at day 30 (B) obtained with film deposition on carrier method. 
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Table XI – DSC data of proliposomes with 2% of LEM2 at the day of production and at day 30, obtained with 
film deposition on carrier method. 
  
 
 
Figure 48 - DSC thermograms from -20 ºC to 240 ºC at 10 ºC/min of proliposomes with 2% of LEM2 at the day 
of production (A) and at day 30 (B) obtained with freeze drying method. 
 
 
Table XII – DSC data of proliposomes with 2% of LEM2 at the day of production and at day 30, obtained with 
freeze drying method. 
Day Area 
(J/g) 
Onset 
(ºC) 
Peak 
(ºC) 
End 
(ºC) 
0 -268.3 165.5 168.9 170.6 
30 -228.1 165.3 169.2 171.3 
 
Day Area 
(J/g) 
Onset 
(ºC) 
Peak 
(ºC) 
End 
(ºC) 
0 -260.3 160.4 170.4 174.1 
30 -267.1 165.8 172.8 177.0 
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Spray dried proliposomes, 30 days after the production exhibited a lower enthalpy, as 
observed for freeze dried proliposomes. Also, the onset temperature of the peak decreased 
and the peak became narrower (Figure 49 and Table XIII). 
 
   
Figure 49 - DSC thermograms from -20 ºC to 240 ºC at 10 ºC/min of proliposomes with 2% of LEM2 at the day 
of production (A) and at day 30 (B) obtained with spray drying method. 
 
 
Table XIII – DSC data of proliposomes with 2% of LEM2 at the day of production and at day 30 obtained with 
spray drying method. 
Day Area 
(J/g) 
Onset 
(ºC) 
Peak 
(ºC) 
End 
(ºC) 
0 -240.4 159.6 167.2 170.2 
30 -219.5 157.5 165.5 169.2 
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3.6.2. Characterization of liposomes 
 
3.6.2.1. Particle size 
 
 Figures 50 to 52 present the variation on the size of liposomes, 30 days after of the 
production of proliposomes. For the film deposition on carrier (Figure 50) and spray drying 
method (Figure 52), no statistically significant alterations were found in the effective 
diameter after 30 days of the production of proliposomes.  
By contrast, the effective diameter of liposomes hydrated from freeze dried 
proliposomes significantly increased 30 days after proliposome production (p < 0.05) 
(Figure 51). This indicates physical instability of liposomes when using freeze drying to 
produce proliposomes, probably due to the formation of lipid aggregates. However, film 
deposition on carrier and spray drying proliposomes seem to prevent the physical instability. 
At the day 30, the polydispersity indexes were similar to those measured at the day of 
production, for three methods (Appendix III).  
  
 
Figure 50 – Box and whiskers plot of effective diameter of liposomes formed by hydration of proliposomes 
produced by film deposition on carrier, with 2% of LEM2, at the day of production and at day 30. Each box 
represents three individual batches.  
95 
 
 
Figure 51 – Box and whiskers plot of effective diameter of liposomes formed by hydration of proliposomes 
produced by freeze drying, with 2% of LEM2, at the day of production and at day 30. Each box represents three 
individual batches. Statistical significance: 
*
 p = 0.005. 
 
 
Figure 52 – Box and whiskers plot of effective diameter of liposomes formed by hydration of proliposomes 
produced by spray drying, with 2% of LEM2, at the day of production and at day 30. Each box represents three 
individual batches.  
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3.6.2.2. Zeta potential 
 
The zeta potential of liposomes, 30 days after the production of liposomes is shown in 
Figures 53 to 55. Liposomes hydrated from film deposition on carrier proliposomes 
(Figure 53) presented a significantly more negative zeta potential (p < 0.o5). 
For the other studied methods, no significant differences in the surface charge of 
liposomes were observed (Figure 54 and 55). 
 
  
 
Figure 53 – Box and whiskers plot of zeta potential of liposomes formed by hydration of proliposomes produced 
by film deposition on carrier, with 2% of LEM2, at the day of production and at day 30. Each box represents three 
individual batches. Statistical significance: 
*
 p = 0.018. 
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Figure 54 – Box and whiskers plot of zeta potential of liposomes formed by hydration of proliposomes produced 
by freeze drying, with 2% of LEM2, at the day of production and at day 30. Each box represents three individual 
batches.  
 
 
Figure 55 – Box and whiskers plot of zeta potential of liposomes formed by hydration of proliposomes produced 
by spray drying, with 2% of LEM2, at the day of production and at day 30. Each box represents three individual 
batches. 
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3.6.2.3. Entrapment efficiency 
 
Figures 56 to 58 present the entrapment efficiency of the hydrated proliposomes 30 
days after the production of proliposomes. Although the three methods presented lower 
entrapment efficiencies at day 30, none of those alterations presented statistically 
significance. When the processes of oxidation and hydrolysis of phospholipids take place, they 
lead to chemical instability on liposomes, increasing the permeability of liposomes 10. Thus, 
the absence of significant changes in the entrapped drug on liposomes might be an indicator 
that the instability of liposomes may be prevented by the use of proliposomes.  
  
 
Figure 56 – Box and whiskers plot of entrapment efficiency of liposomes formed by hydration of proliposomes 
produced by film deposition on carrier, with 2% of LEM2, at the day of production and at day 30. Each box 
represents three individual batches.  
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Figure 57  - Box and whiskers plot of entrapment efficiency of liposomes formed by hydration of proliposomes 
produced by freeze drying, with 2% of LEM2, at the day of production and at day 30. Each box represents three 
individual batches.  
 
 
 
Figure 58 – Box and whiskers plot of entrapment efficiency of liposomes formed by hydration of proliposomes 
produced by spray drying, with 2% of LEM2, at the day of production and at day 30. Each box represents three 
individual batches. 
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From the characterization of liposomes obtained from proliposomes 30 days after 
their production, it seems that spray drying presents a better stability when compared to film 
deposition on carrier and freeze drying methods. 30 days after the production of 
proliposomes, film deposition on carrier powders presented significant alterations in zeta 
potential and freeze drying lead to a significant increase in the effective diameter of 
liposomes, while no significant alterations were observed for spray dried proliposomes.  
Proliposomes were kept at room temperature for 30 days. Their storage at lower 
temperature would probably improve their stability. Janga et al. reported the production of 
stable film deposition on carrier proliposomes for 90 days, under refrigerated temperatures 
(4 ± 2 ºC) 102. 
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CHAPTER 4  - CONCLUSIONS AND FUTURE WORK 
 
 Liposomes are prone to different levels of instability, restricting their shelf-life and 
their clinical application. Proliposomes have been studied as an alternative approach in an 
attempt to overcome stability problems of liposomes. 
 Among the different methods to produce proliposomes, film deposition on carrier, 
freeze drying and spray drying were used in this dissertation to incorporate the synthetic 
xanthone derivative LEM2, with a promising antitumor effect. Xanthone usually present 
poor solubility and their encapsulation in nanosystems might be a strategy to solve the 
solubility problem. 
 LEM2 was effectively synthesized according to a previous protocol, with a good yield. 
The three methods used to prepare proliposomes could effectively encapsulate LEM2. Each 
method produced a powder with different properties and with distinct surface morphologies. 
Spray drying method produced powders having a more uniform surface morphology, with 
spherical particles.  
The hydration of proliposomal powders was effective in converting them in liposomes, 
which presented medium effective diameters in the nanometer scale and good zeta potential 
values. Different percentages of LEM2 in the formulation were studied and the maximum 
entrapment efficiency occurs when LEM2 is present at 2% of the total formulation. The 
entrapment efficiency ranged from about 48% to 63%, for that LEM2 percentage in the 
formulation.  
The stability of proliposomes was also accessed and spray drying presented the better 
stability profile, with no significant alterations in the properties of liposome, 30 days after the 
production of proliposomes. Film deposition on carrier showed significant altered zeta 
potential after 30 days of production and freeze drying presented significant alterations in the 
effective diameter of liposomes, 30 days after the production. 
From the studied methods, spray drying seems to be most promising for the 
manufacture of proliposome formulations. Although spray drying presented the lower 
entrapment efficiency for LEM2, this method produces stable proliposomes with a uniform 
morphology.  
Although spray dried proliposomes have shown to be stable 30 days after their 
production, further studies should be carried out to infer their stability for a prolonged period 
of time. Also, the stability of proliposomes should be investigated at different conditions, 
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mainly at different temperatures for the three production methods. The instability presented 
by film deposition on carrier and freeze dried proliposomes might be solved by the alteration 
of their storage condition. 
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CHAPTER 5  - MATERIAL AND METHODS  
 
5.1. General Methods  
 
Lipoid E80 (egg phospholipids with 80% of phosphatidylcholine) was a gift from Lipoid, 
cholesterol was purchased from Acofarma and methanol used in HPLC was purchased from 
VWR chemicals, with HPLC grade. Mannitol and all the other reagents and solvents were 
purchased from Sigma Aldrich, and had no further purification process. Solvents were 
evaporated using rotary evaporator under reduced pressure, Buchi Waterchath B-480. All 
reactions were monitored by TLC carried out on precoated plates with 0.2 mm of thickness 
using Merck silica gel 60 (GF254). The UV light at 254 and 365 nm was used for visualization 
of chromatograms. Microwave (MW) reactions were performed in glassware open vessel 
reactors in a MicroSYNTH 1600 Microwave Labstation from Millestone (ThermoUnicam, 
Portugal). The internal reaction temperature was controlled by a fiber-optic probe sensor. 
Purification of the synthesized compounds was performed by chromatography flash column 
using Merck silica gel 60 (0.040-0.063 mm), chromatography flash cartridge (GraceResolv®, 
Grace Company, Deerfield, IL, USA). The purity of each compound was qualitatively accessed 
by TLC using two different chromatographic conditions. The ultrapure water was purified by 
the Direct-Q® purification system of Millipore. 
 
 
5.2. Synthesis of the carbaldehydic xanthone derivative LEM2  
 
5.2.1. Synthesis of benzophenone intermediate 3, (2-hydroxy-3,4-
dimethoxy-6-methylphenyl) (methoxyphenyl) methanone  
 
AlCl3 anhydrous (18.3 g, 137.2 mmol) was added to a dry ether solution (200 ml) of 2-3,4,5- 
trimethoxytoluene (1, 10 g, 54.88 mmol) and methoxybenzoyl chloride (2, 11.2 g, 65.85 
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mmol). The resulting deep red mixture was stirred at room temperature, overnight, under N2. 
The reaction was monitored by TLC using n-hexane/ethyl acetate in a proportion of 7:3, using 
the reagents as control. After completing the reaction, the suspension was acidified with HCl 
5M and purified by a liquid-liquid extraction with chloroform (100 ml). The organic layer was 
dried with anhydrous sodium sulphate and concentrated under reduced pressure, resulting in 
a brown oil that was used in the next step without further purification (procedure adapted 
from 93).  
 
5.2.2. Synthesis of 3,4-diethyl-1-methyl-9H-xanthen-9-one (4): cyclization 
of benzophenone intermediate 3  
 
To a solution of NaOH (24 g, 0.6 mol) in MeOH (150 ml) and water (100 ml), the crude 
material containing 327,8 mg of (2-hydroxy-3,4-dimethoxy-6-methylphenyl) 
(methoxyphenyl) methanone (3) was added. The mixture was submitted to microwave (MW) 
irradiation, at open vessel conditions, for 8.5h, at 300 W of potency, 75 ºC of temperature and 
1 bar of pressure. After completing the reaction and cooling at room temperature, the white 
solid formed was filtered under vacuum, washed with MeOH and dried. The retained solid 
was further submitted to a liquid-liquid extraction with dichloromethane (5 x 100 ml). The 
organic layer was dried with anhydrous sodium sulphate and concentrated under reduced 
pressure. The mother liquor resulting from the vacuum filtration was, again, filtered under 
vacuum, washed with MeOH and dried. The progression of reaction and the purification and 
identity steps were monitored by TLC using n-hexane/ethyl acetate in a proportion of 7:3, 
using a standard previously obtained as control. The experimental procedure was adapted 
from 94.  
 
5.2.3. Synthesis of 1-(dibromomethyl)-3,4-dimethoxy-9H-xanthen-9-one 
(5)  
 
A mixture of 3,4-diethyl-1-methyl-9H-xanthen-9-one (4, 2.50 g, 9.25 mmol), N-
bromosuccinimide (3.29 g, 2.0 eq.) and benzoyl peroxide (0.67g, 0.3 eq.) in carbon 
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tetrachloride (80 ml) was refluxed for 2 h, at 80 ºC. The chromatographic system n-
hexane/ethyl acetate (8:2), was used to observe the progression of the reaction, using the 
intermediate 4 and a standard previously obtained as control. Once completed the reaction, 
the suspension was cooled at 0°C and stirred 1-2 h. The precipitate was filtered under vacuum 
and washed with cold carbon tetrachloride. The mother liquor was evaporated and then 
purified by a flash column chromatography (silica gel, n-hexane/ethyl acetate in gradient). 
The obtained fractions containing the intermediate 5 were collected, concentrated under 
reduced pressure and submitted to a chromatography flash cartridge (silica gel, n-
hexane/ethyl acetate in gradient). The pure fractions were gathered and concentrated under 
reduced pressure to obtain a white solid of 1-(dibromomethyl)-3,4-dimethoxy-9H-xanthen-9-
one (5, 3.14 g, 80%). The purification steps and identity were monitored by TLC using n-
hexane/ethyl acetate (8:2), using a standard previously obtained as control. The experimental 
procedure was adapted from 106.  
 
5.2.4. Synthesis of 3,4-dimethoxy-9-oxo-9H-xanthene-1-carbaldehyde 
(LEM2)  
 
A mixture of the dibromoxanthone derivative 5 (3.14 g, 7.34 mmol) and ionic liquid, 1-butyl-
3-methylimidazolium tetrafluoroborate (6,85 ml, 5 eq.) mixed with water was heated at 100°C 
and refluxed for 2.5 h. The mobile phase n-hexane/ethyl acetate (8:2) was used to observe the 
progression of reaction, using the intermediate 5 as control. The reaction was allowed to cool 
at room temperature and extracted with ethyl acetate (10 x 150 ml). The organic layer was 
dried with anhydrous sodium sulphate, concentrated under reduced pressure and the crude 
material was purified using a chromatography flash cartridge (silica gel, n-hexane/ethyl 
acetate in gradient). The pure fractions were gathered and concentrated under reduced 
pressure. The impure fractions, after being concentrated under reduced pressure, were 
crystallized from ethyl acetate/n-hexane (2:1). The obtained crystals were filtered under 
vacuum and washed with cold n-hexane. The purification steps were monitored by TLC using 
n-hexane/ethyl acetate (8:2), using the intermediate 5 as control. A light yellow solid was 
obtained, corresponding to 3,4-dimethoxy-9-oxo-9H-xanthene-1-carbaldehyde (LEM2, 1.33 
g, 64%). The experimental procedure described here was adapted from 97.  
 
110 
 
5.3. Development of an HPLC method to quantify LEM2  
 
The HPLC method was performed using a Thermo Scientific™ Dionex™ UltiMate™ 3000 
system. The stationary phase used was a ACE C18 column with a particle size of 5 µm, 
with length of 25 cm and internal diameter of 4.6 mm (ACE). The samples were analyzed 
with the mobile phase water : methanol (25:75), using a isocratic elution, at a flux of 1.0 
ml/min.  
Stock standard solutions of LEM2 (100 µg/ml) were prepared in water : methanol (25:75). 
Standard solutions were obtained by dilution of the freshly prepared stock standard solution 
with water : methanol (25:75) to give eight different concentrations over the range of interest 
(0,25 to 6,00 µg/ml). The peak areas of LEM2 for each standard concentration were 
determined from the chromatogram. Data were fitted to least squares linear regression to 
obtain a calibration curve. Calibration curves were prepared and analyzed in triplicate on 
three different days. 
 
 
5.4. Preliminary studies for the development of proliposomal solutions 
 
Mannitol was sieved to collect the fraction with particle size < 125 µm. To prepare weight 
ratios of carrier: lipid (1:1), (2.5:1), (5:1) and (10:1), 0.2g, 0.5g, 1g and 2g of mannitol 
respectively, were placed in the round-bottomed flask, which was rotated under reduced 
pressure at 75 – 80 ºC, for about 30 minutes. The proliposomal formulation with no drug was 
prepared by a mixture of 171.02 mg of phosphatidylcholine and 29.0 mg of cholesterol (molar 
ratio 3:1) dissolved in 10 ml of EtOH. After the drying of mannitol, the temperature of the 
water bath was lowered and the ethanolic solution was added, in aliquots, to the round-
bottomed flask, continuously rotated under reduced pressure until the solution had 
penetrated into the mannitol matrix. The solvent was completely evaporated. The 
experimental procedure was adapted from 49. 
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5.5. Production of proliposome 
 
The lipid part of proliposomes was composed of a mixture of egg phospholipids with 80% of 
phosphatidylcholine and cholesterol. The carrier material used was mannitol.  
 
5.5.1. Film deposition on carrier 
 
Mannitol was sieved to collect the fraction with particle size < 125 µm, and 1.67 g of mannitol 
were placed in the round-bottomed flask, which was rotated under reduced pressure at 75 – 
80 ºC, for about 30 minutes. The proliposomal formulation with no drug was prepared by a 
mixture of 142.52 mg of phosphatidylcholine and 24,17 mg of cholesterol (molar ratio 3:1) 
dissolved in 10 ml of EtOH. Proliposomes with 0.8%, 2% and 4% of LEM2, were prepared by 
adding respectively 1.33 mg, 3.33 mg and 6.67 mg of the compound to the ethanolic solution 
of lipids. After the drying of mannitol, the temperature of the water bath was lowered and the 
ethanolic solution was added, in aliquots, to the round-bottomed flask, continuously rotated 
under reduced pressure until the solution had penetrated into the mannitol matrix. The 
solvent was completely evaporated. The obtained proliposome powders were stored in a 
desiccator at room temperature. The experimental procedure was adapted from 49. 
 
5.5.2. Freeze drying 
 
Mannitol was sieved to collect the fraction with particle size < 125 µm. The proliposomal 
formulation with no drug was prepared by a mixture of 142.52 mg of phosphatidylcholine and 
24,17 mg of cholesterol (molar ratio 3:1) and dissolved in 15 ml of EtOH. Proliposomes with 
0.8%, 2% and 4% of LEM2, were prepared by adding respectively 1.33 mg, 3.33 mg and 6.67 
mg of the compound to the ethanolic solution of lipids. The solution was subjected to 
ultrasonic agitation for 15 min. Mannitol was added to the solution and the volume of 100 ml 
was completed with distilled water. The solution was placed at a freeze dryer (VirTis Wizard 
2.0, Advantage Plus, VirTis SP Scientific) and was initially frozen at -30 ºC, for 120min, at a 
vacuum pressure of 150 mTorr and with the condenser temperature -60 ºC. The primary 
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drying occurred at 20 ºC, for 600 min and the vaccum pressure 150 mTorr and a secondary 
drying stage was performed at 25 ºC, for 600 min and at the vacuum pressure of 100 mTorr. 
 
5.5.3. Spray drying 
 
A solution of 1% of mannitol in distilled water was sprayed through a 0.7 µm nozzle using a 
Nano Spray Dryer B-90 (Büchi, Switzerland) at an inlet temperature of 80 °C, an atomizing 
pressure of 33 mbar, and a feeding rate of 90 l/min. The outlet temperature was 37 - 38 °C. 
The product was separated and collected by the cyclone and then directed into the collecting 
chamber. The obtained mannitol particles were used as the carrier material to produce 
proliposomes by spray drying. 
The proliposomal formulation with no drug was prepared by a mixture of 142.52 mg of 
phosphatidylcholine and 24,17 mg of cholesterol (molar ratio 3:1) and dissolved in 15 ml of 
EtOH. Proliposomes with 2% of LEM2, were prepared by adding 3.33 mg of the compound to 
the ethanolic solution of lipids. The solution was subjected to ultrasonic agitation for 15 min. 
Spray dried mannitol was added to the solution and the volume of 100 ml was completed with 
distilled water. The solution was subjected to ultrassonic agitation for 15 min in order to 
disaggregate mannitol particles. The solution was submitted to spray drying at a inlet 
temperature of 80 °C, an atomizing pressure of 33 mbar, and a feeding rate of 90 l/min. The 
outlet temperature was 37 - 38 °C. The obtained proliposome powders were stored in a 
desiccator at room temperature. The experimental procedure was adapted from 59. 
 
 
5.6. Analysis of proliposome powders 
 
5.6.1. Surface morphology of proliposomes 
 
 The surface morphology of proliposomes was analyzed by SEM. The SEM / EDS exam 
was performed using a High resolution (Schottky) Environmental Scanning Electron 
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Microscope with X-Ray Microanalysis and Electron Backscattered Diffraction analysis: 
Quanta 400 FEG ESEM / EDAX Genesis X4M.  Samples were coated with an Au/Pd thin film 
for 90 sec. and with a 15mA current, by sputtering, using the SPI Module Sputter Coater 
equipment.  Each image contains a databar with the most important analysis conditions.  
 
5.6.2. Thermal behaviour of proliposomes 
 
Differential scanning calorimetry (DSC) analysis was carried out using a Netzsch DSC 200 F3 
differential scanning calorimeter and Netzsch proteus thermal analysis software. DSC 
analyses were performed on the ingredients of the formulation and on proliposome powders 
on the day of production. In this way, the samples were weighed directly in aluminum pans 
and scanned between -20 °C and 240 °C at a heating rate of 10 °C/min. 
 
 
5.7. Hydration of proliposomes 
 
Proliposomes were hydrated to form liposomes. 60 mg of the proliposome powder were 
weighted and hydrated with 2 ml of ultrapure water and agitated manually for 1 min (adapted 
from 46). The obtained solution was filtered through a 5 µm nitrocellulose membrane filter 
(Minisart, Germany) to remove possible lipid aggregates. 
 
5.7.1. Surface morphology of liposomes 
 
 The surface morphology of liposomes was analyzed by CryoSEM. The SEM exam was 
performed using a High resolution Scanning Electron Microscope with X-Ray Microanalysis 
and CryoSEM experimental facilities: JEOL JSM 6301F/ Oxford INCA Energy 350/ Gatan 
Alto 2500. The specimen was rapidly cooled (plunging it into sub-cooled nitrogen – slush 
nitrogen) and transferred under vacuum to the cold stage of the preparation chamber.  The 
specimen was fractured, sublimated (‘etched’) for 90sec. at -90°C, and coated with Au/Pd by 
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sputtering for 30 sec and with a 12mA current. The sample was then transferred into the SEM 
chamber. The sample was studied at a temperature of -150°C. The conditions in which images 
were obtained are in the respective labels. 
 
5.7.2. Particle size measurement  
 
The particle size and polydispersity index was determined by dynamic light scattering (DLS), 
using a ZetaPALS, ZetaPotential Analyzer (Holtsville, NY, USA). Prior to the measurements, 
all samples were diluted (1:10) using purified water to yield a suitable scattering intensity, the 
average count rate indicates that the dilution applied to the formulations was appropriate. 
The measurements were always performed six times for each sample. The zetaPALS particle 
sizing software was used to analyze the obtained data.  
 
5.7.3. Zeta potential measurement  
 
Zeta potential of liposomes was measured using a ZetaPALS, ZetaPotential Analyzer 
(Holtsville, NY, USA). Prior to the measurements, all samples were diluted (1:10) using 
purified water to yield a suitable scattering intensity. The measurements were always 
performed six times for each sample. The PALS zeta potential analyzer software was used to 
analyze the obtained data. 
 
5.7.4. Entrapment efficiency of liposomes 
 
The amount of encapsulated drug within the nanoparticles was measured to calculate the 
encapsulation efficiency. Briefly, 220 mg of the freshly prepared proliposomal formulation 
was hydrated with 2 ml of ultrapure water and agitated manually for 1 min. The solution was 
filtered through a 5 µm nitrocellulose membrane filter (Minisart, Germany) to remove 
unencapsulated drug crystals. Then, 7 ml of methanol was added to 1 ml of filtered 
formulation and thoroughly mixed to extract the drug from the lipid matrix. The mixture was 
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then centrifuged at 5000 rpm for 15 min and the supernatant was diluted with methanol (1:1) 
and centrifuged at 5000 rpm for 5 min and the supernatant was filtered through a 0,45 µm 
PTFE syringe filter (Olimpeak by Teknokroma, Ireland). If needed, the supernatant was again 
diluted with the mixture of solvents water: methanol (25:75) to the HPLC assay calibration 
range. The amount of drug in the filtered supernatant was measured by HPLC. The amount of 
drug in the filtered formulation was then calculated considering the dilution factor. The 
experimental procedure was adapted from 107. The entrapment efficiency was calculated by 
the following equation 2: 
 
𝐸𝐸 (%) =
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑓𝑖𝑙𝑡𝑒𝑟𝑒𝑑 𝑓𝑜𝑟𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛
𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔
 𝑥 100 
  
 
5.8. Stability studies 
 
After the production of proliposomes, they were kept at a desiccator at room temperature. 
Their stability was studied 30 days after the storage. DSC data of proliposome powders was 
analyzed. After hydration of proliposomes, the particle size, zeta potential and entrapment 
efficiency of liposomes were also analyzed. 
 
 
5.9. Statistical analysis 
 
For the characterization of liposomes hydrated from proliposomes at the day of production 
results are shown as the mean ± standard deviation  of 3 different batches of the same 
formulation. The t-test and the one-way analysis of variance (ANOVA) were performed to 
compare two or multiple groups, respectively. If the group by each time interaction was 
significantly different (P < 0.05), differences between groups were compared within a post 
hoc test (Tukey HSD). All statistical analyses were performed with the software IBM SPSS 
Statistics 23 (SPSS Inc., Chicago, USA). 
 
Equation 2 
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CHAPTER 7 – APENDICES  
 
 
Appendix I   - Characterization of liposomes formed by hydration of 
proliposomes with different carrier : lipid weight ratio, by freeze drying. 
 
Table XIV - Characterization of liposomes formed by hydration of proliposomes with different carrier : lipid 
weight ratio, by freeze drying. 
Carrier : lipid 
weigh ratio 
Effective diameter 
(nm) 
Polydispersity Zeta potential 
(mV) 
1 : 1 470.2 ± 32.7 0.328 ± 0.014 -32.03 ± 3.58 
2.5 : 1 516.1 ± 4.0 0.324 ±0.010 -36.45 ± 3.31 
5 : 1 529.0 ± 18.7 0.326 ± 0.009 -40.16 ± 11.40 
10 : 1 443.6 ± 26.4 0.318 ± 0.030 -41.32 ± 0.74 
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Appendix II - Characterization of liposomes formed by hydration of 
proliposomes at the day of production  
 
Table XV - Characterization of liposomes formed by hydration of film deposition on carrier proliposomes at the 
day of production. 
Percentage of 
LEM2 
Effective 
diameter 
(nm) 
Polydispersity Zeta potential 
(mV) 
Entrapment 
efficiency 
(%) 
No drug 546.5 ± 66.0 0.330 ± 0.03 -47.38 ± 8.19  
0.8 %  592.3 ± 42.6 0.344 ± 0.007 -38.31 ± 0.28 30.92 ± 8.80 
2 % 614.6 ± 39.1 0.335 ± 0.007 -38.11 ± 0.06 51.92 ± 21.91 
4 % 659.1 ± 152.4 0.353 ± 0.019 -38.38 ± 0.21 25.98 ± 23.81 
 
 
Table XVI - Characterization of liposomes formed by hydration of freeze dried proliposomes at the day of 
production. 
 
Percentage of 
LEM2 
Effective 
diameter 
(nm) 
Polydispersity Zeta potential 
(mV) 
Entrapment 
efficiency 
(%) 
No drug 443.6 ± 26,8 0.318 ± 0.030 -41.84 ± 2.66  
0.8 % 450.6 ± 38.0 0.350 ± 0.015 -37.83 ± 1.49 24.23 ± 5.74 
2 % 428.2 ± 18.2 0.337 ± 0.025 -38.63 ± 0.40 62.68 ± 31.55 
4 % 410.8 ± 17.2 0.335 ± 0.025 -38.11 ± 2.62 4.72 ± 0.55 
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Table XVII - Characterization of liposomes formed by hydration of spray dried proliposomes at the day of 
production. 
  
Percentage of 
LEM2 
Effective 
diameter 
(nm) 
Polydispersity Zeta potential 
(mV) 
Entrapment 
efficiency 
(%) 
No drug 243.2 ± 34.0 0.272 ±0.024 -44.93 ± 2.84  
2% 272.2 ± 20.9 0.314 ± 0.004 -38.30 ± 0.19 47.54 ± 24.73 
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Appendix III – Characterization of liposomes formed by hydration of 
proliposomes at the day 30. 
 
Table XVIII - Characterization of liposomes formed by hydration of film deposition on carrier proliposomes at 
the day 30. 
Day Effective 
diameter  
(nm) 
Polydispersity Zeta potential 
(mV) 
Entrapment 
efficiency 
(%) 
0 614.6 ± 39.1 0.335 ± 0.007 -38.11 ± 0.06 51.92 ± 21.91 
30 625.9 ± 62.1 0.329 ± 0.019 -38.50 ± 0.16 10.47 ± 1.25 
 
 
Table XIX - Characterization of liposomes formed by hydration of freeze dried proliposomes at the day 30. 
Sample Effective 
diameter  
(nm) 
Polydispersity Zeta potential 
(mV) 
Entrapment 
efficiency 
(%) 
0 428.23 ± 18.24 0.337 ± 0.025 -38.63 ± 0.40 62.68 ± 31.55 
30 522.03 ± 33.57 0.327 ± 0.012 -38.21 ± 0.24 22.22 ± 24.13 
 
 
Table XX - Characterization of liposomes formed by hydration of spray dried proliposomes at the day 30. 
Day Effective 
diameter 
(nm) 
Polydispersity Zeta potential 
(mV) 
Entrapment 
efficiency 
(%) 
0 272.2 ± 20.9 0.314 ± 0.004 -38.30 ± 0.19 47.54 ± 24.73 
30 282.3 ± 64.0 0.297± 0.035 -38.35 ± 0.24 28.68 ±13.71 
 
